Newsroom | Medtronic | 2012 Press Releases

2012 Press Releases


201720162015201420132012
Search News Releases
 
DateTitle  
12/31/12Mallinckrodt Launches Generic Version of CONCERTA® in U.S.
Company to hold six-month exclusivity on 27, 36 and 54 milligram dosage strengths of ADHD treatment ST. LOUIS--(BUSINESS WIRE)--Dec. 31, 2012-- Mallinckrodt, the Pharmaceuticals business of Covidien (NYSE: COV), today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market a generic version of CONCERTA® (methylphenidate HCl) Extended-Release (ER) Tablets USP (CII) in 27, 36 ... 
 Printer Friendly Version
12/26/12Covidien Announces Definitive Agreement to Acquire CV Ingenuity
DUBLIN--(BUSINESS WIRE)--Dec. 26, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced a definitive agreement to acquire CV Ingenuity. The companies expect to complete the acquisition in the first calendar quarter of 2013. Financial terms of the transaction were not disclosed. CV Ingenuity, a privately-held company based in Fremont, CA, is focused on improving patient outcomes in the treatme... 
 Printer Friendly Version
12/20/12Covidien Announces Five-Year Results from the ClosureFast™ Long-Term European Multi-Center Study in Patients with Lower Limb Venous Disease
Study Demonstrates Long-Term Durability of the ClosureFast™ Radiofrequency Ablation System for Treatment of Chronic Venous Insufficiency MANSFIELD, Mass.--(BUSINESS WIRE)--Dec. 20, 2012-- Covidien (NYSE:COV), a leading global provider of healthcare products, today announced the five-year results of the ClosureFast™ Long-Term European Multi-Center Study in patients with Chronic Venous Insufficiency (CVI). This study evaluates the five-ye... 
 Printer Friendly Version
12/19/12Covidien to Present at J.P. Morgan Healthcare Conference
MANSFIELD, Mass.--(BUSINESS WIRE)--Dec. 19, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, will present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, California, on January 7, 2013. Joe Almeida, Chairman, President and Chief Executive Officer, will discuss the Company in a presentation scheduled to begin at 8:30AM PT (11:30AM ET). A live audio webcast of the presentation can be a... 
 Printer Friendly Version
12/17/12One-Year Results from the Symplicity HTN-2 Randomized Controlled Trial Published in Circulation
Published data demonstrate the Symplicity™ renal denervation system provides blood pressure reduction in patients with treatment-resistant hypertension sustained to 12 months MINNEAPOLIS – December 17, 2012 – Medtronic, Inc. (NYSE: MDT) today announced that one-year results from Symplicity HTN-2, the first randomized clinical trial investigating renal denervation, were published online before print in Circulation, the Journal of the American Heart Association. These data showed patients who ... 
Download PDFPrinter Friendly Version
12/17/12Covidien Expands Production of Kangaroo™ Enteral Feeding Pumps & Sets
MANSFIELD, Mass.--(BUSINESS WIRE)--Dec. 17, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced a significant capacity expansion of its Kangaroo™ ePump and Kangaroo™ Joey enteral feeding pumps and sets. This announcement comes in the wake of a recent announcement of a competitor’s exit from the enteral feeding pump market in the United States. “Covidien has increased its inventory of enteral feedi... 
 Printer Friendly Version
12/12/12Covidien plc to Report First-Quarter Results on January 25, 2013
DUBLIN--(BUSINESS WIRE)--Dec. 12, 2012-- Covidien plc (NYSE: COV) will report first-quarter results on January 25, 2013, before trading begins. The Company will hold a conference call for investors at 8:30 a.m. ET. The call can be accessed in the following ways: At Covidien’s website: http://investor.covidien.com By telephone: For both “listen-only” participants and those participants who wish to ta... 
 Printer Friendly Version
12/10/12Medtronic CEO Omar Ishrak to Speak at JP Morgan Healthcare Conference
MINNEAPOLIS – Dec 10, 2012 – Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the JP Morgan 31st Annual Healthcare Conference on Monday, January 7, 2013 in San Francisco. Omar Ishrak, chairman and chief executive officer of Medtronic will make a presentation about Medtronic beginning at 9:30 a.m. PST (11:30 a.m. CST). A live audio webcast of the presentation will be available on January 7, 2013, by clicking on the Investors l... 
Download PDFPrinter Friendly Version
12/06/12Medtronic Introduces Cervical Facetlift(SM) ID/S Surgical Technique
MEMPHIS, Tenn. – Dec. 6, 2012 – Medtronic, Inc. (NYSE: MDT) the world leader in spinal technology, announced the U.S. launch of the company’s latest addition to their cervical surgical technique portfolio. The announcement was made at the 40th annual meeting of the Cervical Spine Research Society. The CERVICAL FACETLIFTSM ID/S surgical technique is an innovative procedure that indirectly decompresses the neural foramen and stabilizes the cervical spine. This technique is accomplished by placing... 
Download PDFPrinter Friendly Version
12/06/12Medtronic Announces Accelerated Cash Dividend for Third Quarter of Fiscal Year 2013
MINNEAPOLIS – December 6, 2012 – The board of directors of Medtronic, Inc. (NYSE:MDT) today approved a cash dividend of $0.26 per share of the Company’s common stock. The dividend is payable on December 28, 2012, to shareholders of record at the close of business on December 17, 2012. This accelerated quarterly dividend is intended to replace the dividend that would have been declared in January 2013. About Medtronic Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the gl... 
Download PDFPrinter Friendly Version
12/06/12HeartWare Presentation at the Oppenheimer 23rd Annual Healthcare Conference to be Webcast
FRAMINGHAM, Mass. and SYDNEY, Dec. 6, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Oppenheimer 23rd Annual Healthcare Conference at 10:00 a.m. EST on Thursday, December 13, 2012.  The conference is being held December 12-13 at the... 
 Printer Friendly Version
12/04/12Covidien Declares Accelerated Quarterly Cash Dividend
DUBLIN--(BUSINESS WIRE)--Dec. 4, 2012-- Covidien plc (NYSE: COV) today announced that its Board of Directors has declared a quarterly cash dividend of $0.26 per ordinary share. The dividend is payable on December 27, 2012, to shareholders of record as of the close of business on December 14, 2012. This accelerated quarterly dividend is intended to be in lieu of the quarterly dividend which would have been declared in January 2013. ... 
 Printer Friendly Version
12/04/12Medtronic CFO Gary Ellis To Speak At Oppenheimer Healthcare Conference
MINNEAPOLIS – Dec 4, 2012 – Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Oppenheimer 23rd Annual Healthcare Conference on Wednesday, December 12, 2012, in New York City. Gary Ellis, senior vice president and chief financial officer of Medtronic, will make a presentation about Medtronic beginning at 2:45 p.m. EST (1:45 p.m. CST). A live audio webcast of the presentation will be available on December 12, 2012, by clicking... 
Download PDFPrinter Friendly Version
12/04/12Covidien Introduces New Surgical Device for Meniscal Repair
AS Meniscal™ Repair Device Combines Best Surgical Techniques for Repairing Meniscus Tears NEW HAVEN, Conn.--(BUSINESS WIRE)--Dec. 4, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the launch of the AS Meniscal™ Repair Device. The newest addition to the Company’s line of sports surgery devices, the AS Meniscal Repair Device enables orthopedic surgeons to perform “all-inside,” minimally inva... 
 Printer Friendly Version
12/03/12Medtronic Sentrino® CGM System Gains CE Mark
System Designed to Improve Glucose Control in Critical Care Patients MINNEAPOLIS – December 3, 2012 – Medtronic, Inc. (NYSE:MDT) today announced CE (Conformité Européenne) Mark approval of its innovative Sentrino® Continuous Glucose Management System, the first minimally invasive continuous glucose monitoring (CGM) system specifically designed for use in hospital critical care units (CCU). The Sentrino CGM System provides real-time trend data that serves as an early warning system, allowing ... 
Download PDFPrinter Friendly Version
11/26/12 Medtronic EVP & President Mike Coyle to Speak at Piper Jaffray Healthcare Conference
MINNEAPOLIS – Nov 26, 2012 – Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Piper Jaffray Healthcare Conference on Wednesday, November 28, 2012 in New York. Mike Coyle, executive vice president and president of Medtronic’s Cardiac and Vascular Group will make a presentation about Medtronic beginning at 1:00 p.m. ET (12:00 p.m. CT). A live audio webcast of the presentation will be available on November 28, 2012 by clicki... 
Download PDFPrinter Friendly Version
11/22/12National Institute for Health and Clinical Excellence Recommends Covidien’s BIS Brain Monitoring System
BOULDER, Colo.--(BUSINESS WIRE)--Nov. 22, 2012-- Covidien, a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, today announced that the UK-based National Institute for Health and Clinical Excellence (NICE) recommends the use of electroencephalography (EEG)-based monitors, specifically the Bispectral Index (BIS™) monitor, as an option for measuring depth of anaesthesia. The recommendation specifies that the BIS monitor sh... 
 Printer Friendly Version
11/20/12HeartWare Receives FDA Approval for HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation for Patients with Advanced Heart Failure
- First full-support, miniaturized ventricular assist device approved in U.S. designed to be placed in the pericardial space - - HeartWare Management to Host Investor Conference Call Today at 3:00 pm ET - FRAMINGHAM, Mass. and SYDNEY, Nov. 20, 2012 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure... 
 Printer Friendly Version
11/20/12Medtronic Reports Second Quarter Earnings
Revenue of $4.1 Billion Grew 5% on a Constant Currency Basis; 2% as Reported International Revenue Grew 8% on a Constant Currency Basis; 1% as Reported Company Updates FY13 Revenue Outlook; Reiterates FY13 EPS Guidance MINNEAPOLIS – November 20, 2012 – Medtronic, Inc. (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2013, which ended October 26, 2012. The Company reported worldwide second quarter revenue of $4.095 billion, an increase of 5 percent on a con... 
Download PDFPrinter Friendly Version
11/19/12Medtronic’s Endurant AAA Stent Graft Delivers Durable Outcomes for Abdominal Aortic Aneursym Repair
Two-Year Clinical Data Presented at VEITHsymposium Demonstrate Consistently Strong Performance Worldwide in Pre- and Post-Market Evaluations of Innovative Medical Device MINNEAPOLIS –– Nov. 19, 2012 –– Chosen for nearly one out of every two endovascular abdominal aortic aneurysm repairs worldwide, the Endurant AAA stent graft system from Medtronic, Inc. (NYSE: MDT) continues to show robust results in mid-term follow-up, according to two-year clinical data presented at VEITHsymposium, which c... 
Download PDFPrinter Friendly Version
11/16/12HeartWare Presentation At The 24th Annual Piper Jaffray Healthcare Conference To Be Webcast
FRAMINGHAM, Mass. and SYDNEY, Nov. 16, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 24th Annual Piper Jaffray Healthcare Conference at 8:30 a.m. EST on Wednesday, November 28, 2012.  The conference is being held November 27-28, 2012, at The Ne... 
 Printer Friendly Version
11/16/12First U.S. Patient Treated in Medtronic Clinical Trial Evaluating CoreValve® System in Intermediate-Risk Patients
MINNEAPOLIS – November 16, 2012 – Medtronic, Inc. (NYSE: MDT) today announced the first treatment of a U.S. patient in its global, multicenter, randomized clinical trial comparing the Medtronic CoreValve® System with surgical aortic valve replacement in patients with severe aortic stenosis who are at intermediate risk to undergo open-heart surgery. The Medtronic CoreValve Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial is evaluating the minimally-invasive CoreVal... 
Download PDFPrinter Friendly Version
11/13/12FDA Approves Medtronic Stent Graft for Aortic Transection Repair
New Indication Expands Labeled Uses for Valiant® Captivia® System in U.S.;Six-Month Results of RESCUE Trial Will Be Presented at VEITHsymposium MINNEAPOLIS –– Nov. 13, 2012 –– Consistent with its commitment to clinical excellence, Medtronic, Inc. (NYSE: MDT) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s Valiant® Captivia® stent graft system for the endovascular repair of isolated lesions (excluding dissections) of the descending segment of the th... 
Download PDFPrinter Friendly Version
11/13/12Medtronic to Announce Financial Results for Its Second Quarter of Fiscal Year 2013
MINNEAPOLIS – Nov. 13, 2012 – Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the second quarter of its fiscal year 2013 on Tuesday, November 20, 2012. A news release will be issued at approximately 6:15 a.m. Central Time and will be available at www.medtronic.com/newsroom. The earnings news release will include summary financial information for Medtronic’s second quarter which ended October 26, 2012. Medtronic will host a webcast at 7 a.m. Central Time to discu... 
Download PDFPrinter Friendly Version
11/13/12Medtronic Issues Statement on Court of Appeals Ruling
MINNEAPOLIS – November 13, 2012 – The Federal Circuit Court of Appeals has affirmed the April 2010 jury verdict from the Federal District Court of Delaware that the CoreValve® System infringed a single Andersen patent held by Edwards Lifesciences. The Court of Appeals also remanded the case back to the District Court to consider a potential injunction. While Medtronic respects the court’s ruling, we respectfully disagree with this conclusion and we are evaluating next steps. These legal action... 
Download PDFPrinter Friendly Version
11/09/12HeartWare Presentation At The Lazard Capital Markets 9th Annual Healthcare Conference To Be Webcast
FRAMINGHAM, Mass. and SYDNEY, Nov. 9, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Lazard Capital Markets 9th Annual Healthcare Conference at 10:00 a.m. EST on Tuesday, November 13, 2012.  The conference is being held November 13-14, 2012, at ... 
 Printer Friendly Version
11/09/12HeartWare Reports Third Quarter 2012 Results
- International Revenue Growth of 40% Highlights Third Quarter Performance - - Conference call today at 8:00 a.m. U.S. E.T. - FRAMINGHAM, Mass. and SYDNEY, Nov. 9, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $22.9 million for the third quarter ended September 30, 2012, compared to ... 
 Printer Friendly Version
11/09/12Covidien Reports Fourth-Quarter and Fiscal 2012 Results
View PDF Fourth-quarter and fiscal 2012 results negatively impacted by extra selling week in 2011 and unfavorable foreign exchange rate movement Fourth-quarter net sales down 3% (flat excluding foreign exchange rate movement); Medical Devices sales down 1% (up 2% excluding foreign exchange rate movement) Fourth-quarter diluted GAAP earnings per share from continuing operations were $0.96; excluding specified items, adjusted diluted earnings per share from continuing operations were $1.0... 
 Printer Friendly Version
11/07/12Covidien to Present at Jefferies 2012 Global Healthcare Conference
MANSFIELD, Mass.--(BUSINESS WIRE)--Nov. 7, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, will present at the Jefferies 2012 Global Healthcare Conference in London on November 14, 2012. Coleman N. Lannum, Vice President, Investor Relations, will discuss the Company in a presentation scheduled to begin at 10:00AM local time (5:00AM ET). A live audio webcast of the presentation can be accessed at Covidien’s ... 
 Printer Friendly Version
11/06/12Significantly Better Patient Outcomes Gained from Pacing Both Ventricles in Patients with AV Block and Reduced Pumping Function
Medtronic Biventricular Pacing Reduces Risk of Death and Heart Failure Visits by 27 Percent, Demonstrating Superiority and Real-World Clinical Benefits Compared to Right Ventricular Pacing MINNEAPOLIS and LOS ANGELES – Nov. 6, 2012 – Medtronic, Inc. (NYSE: MDT) today announced interim findings from the BLOCK HF trial, which show that biventricular (BiV) pacing may offer a significant clinical advantage and improved patient outcomes over conventional right ventricular (RV) pacing among patien... 
Download PDFPrinter Friendly Version
11/05/12Medtronic Foundation Donates $250,000 to Hurricane Sandy Relief Efforts
MINNEAPOLIS – Nov. 5 – 2012 – Medtronic, Inc. (NYSE: MDT) announced today a grant of $250,000 from the Medtronic Foundation to the American Red Cross to support relief efforts in areas affected by Hurricane Sandy.   Medtronic employees also are offered five days of paid leave to assist in recovery efforts.  About the Medtronic Foundation The Medtronic Foundation (www.medtronicfoundation.org) is committed to improving the lives of people around the world living with chronic disease,... 
Download PDFPrinter Friendly Version
11/01/12Medtronic Completes Acquisition of China Kanghui Holdings
Accelerates Globalization and Company’s Overall Position in Global Orthopedics Market MINNEAPOLIS, Nov. 1, 2012 – Medtronic, Inc. (NYSE: MDT) announced today that it has completed its acquisition of China Kanghui Holdings (NYSE: KH), a leading provider of orthopedic devices in China. Under the terms of the agreement announced on Sept. 27, 2012, Medtronic will pay approximately $816 million in cash ($30.75 per American depository share). The total value of the transaction, net of Kanghui’s ca... 
Download PDFPrinter Friendly Version
11/01/12HeartWare Schedules Third Quarter Conference Call And Webcast
FRAMINGHAM, Mass. and SYDNEY, Nov. 1, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three months ended September 30, 2012, at 8:00 a.m. U.S. Eastern Standard Time on Friday, November 9, 2012. The Company plans to release the financial results prior to the conference call. The conference call with management will discuss the Company's financial results, highlights from the third quarter an... 
 Printer Friendly Version
10/29/12First Results from Medtronic Engager™ European Pivotal Trial Demonstrate Positive Outcomes
Data Demonstrate High Procedural Success in Late-Breaking Trials Session at the European Association for Cardio-Thoracic Surgery Annual Meeting MINNEAPOLIS – October 29, 2012 – Medtronic, Inc. (NYSE: MDT) today announced promising data from the EngagerTM European Pivotal Trial for the investigational Medtronic EngagerTM Transcatheter Aortic Valve Implantation (TAVI) System. The first results from the multi-center trial support the safety and clinical performance of the valve, which uses a tr... 
Download PDFPrinter Friendly Version
10/26/12 Medtronic Gains FDA Clearance for New Pediatric Oxygenation System for Neonate, Infant and Pediatric Cardiopulmonary Bypass Surgery
Advanced System Serves as Child’s Lungs During Lifesaving Open-Heart Surgery and Provides Perfusionists with Options for a Broader Range of Patients MINNEAPOLIS – October 26, 2012 – Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and the first U.S. clinical use of its new Affinity Pixie® Oxygenation System. The system allows for broader use in children of various sizes and easy set-up and use by perfusionists during lifesaving open-heart (... 
Download PDFPrinter Friendly Version
10/24/12Medtronic Response to Senate Finance Committee Staff Report on INFUSE® Bone Graft
MINNEAPOLIS – Oct. 24, 2012 – A report by the staff to the Chairman of the U.S. Senate Committee on Finance, Max Baucus, and staff to Senator Charles Grassley, raises a number of questions regarding peer-reviewed medical journal articles related to INFUSE® Bone Graft.  Medtronic cooperated with the inquiry, providing documents as requested and addressing questions raised by the Committee Staff.  As Medtronic has repeatedly stated, patient safety and integrity are its highest priorities... 
Download PDFPrinter Friendly Version
10/24/12Medtronic Engages Cardiologists in ‘World Diabetes Day’
Efforts Aim to Raise Awareness of Link Between Diabetes and Coronary Artery Disease MINNEAPOLIS –– Oct. 24, 2012 –– Reinforcing its commitment to people with diabetes, Medtronic, Inc. (NYSE: MDT) is promoting its long-standing partnership with the International Diabetes Federation (IDF) through a new initiative surrounding “World Diabetes Day” on Nov. 14 that aims to engage interventional cardiologists worldwide in raising awareness of the connection between diabetes and coron... 
Download PDFPrinter Friendly Version
10/24/12Medtronic Introduces Innovative Procedure for Minimally Invasive Spinal Fusion
MEMPHIS, Tenn. – Oct. 24, 2012 – Medtronic, Inc. (NYSE: MDT) the world leader in spinal technology, announced today an innovative approach to minimally invasive spinal fusion at the 27th annual meeting of the North American Spine Society in Dallas, TX. The OLIF25™Procedure allows for psoas preserving access to the L2-L5 levels and incorporates Medtronic’s comprehensive surgical platform of access, interbody, neuromonitoring, navigation, fixation and biologic options.  Referred to as Obliqu... 
Download PDFPrinter Friendly Version
10/23/12Medtronic Stent Successfully Treats Long Lesions and Small Vessels, Two Characteristics Typical of Patients with Diabetes, in Multiple Studies
New Data from RESOLUTE Clinical Program Show Strong Performance in Complex Subsets MINNEAPOLIS and MIAMI –– Oct. 23, 2012 –– For the treatment of long lesions and small vessels –– two challenging characteristics of coronary artery disease commonly found in patients with diabetes –– the Resolute drug-eluting stent from Medtronic, Inc. (NYSE: MDT) delivered successful clinical results, according to new data presented at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific... 
Download PDFPrinter Friendly Version
10/23/12Medtronic Introduces ANCHOR FS Facet Fixation System
MEMPHIS, Tenn. – Oct. 23, 2012 – Medtronic, Inc. (NYSE: MDT) the world leader in spinal technology, announced today the latest addition to their minimally invasive spinal fusion portfolio at the 27th annual meeting of the North American Spine Society in Dallas. The ANCHOR FS™ Facet Fixation System is a minimally invasive posterior screw system used in the lumbar region of the spine. It is intended to provide stability by fixation through the facet joints. The ANCHOR FS™ Facet Fixation System in... 
Download PDFPrinter Friendly Version
10/23/12Medtronic Fortifies Spinal Interbody Portfolio
New Products Increase Surgical Options in Lumbar Procedures New Products Increase Surgical Options in Lumbar Procedures MEMPHIS, Tenn. - Oct. 23, 2012– Medtronic, Inc. (NYSE: MDT) the world leader in spinal technology announced today key additions to reinforce its posterior degenerative interbody portfolio.  These new technologies expand the company’s broad innovative offerings for both open and minimally invasive procedural solutions.  The launch features the addition of posterio... 
Download PDFPrinter Friendly Version
10/22/12Analysis Of Medtronic Stent Finds Early Cessation Of Dual Antiplatelet Therapy Caused No Increased Risk Of Blood Clots To One Year
More than 900 Patients in RESOLUTE Clinical Program Interrupted or Discontinued DAPT After 30 Days Following Implant Procedure MINNEAPOLIS and MIAMI –– Oct. 22, 2012 –– Interrupting dual antiplatelet therapy after 30 days following the implantation of a Resolute drug-eluting stent from Medtronic, Inc. (NYSE: MDT) caused no increase in rates of stent thrombosis at one year, according to a new analysis of the global RESOLUTE clinical program presented today at the 24th Annual Transcatheter Car... 
Download PDFPrinter Friendly Version
10/22/12New Study Results Show High Survival Rates and Improved Quality of Life for Patients with Medtronic CoreValve® System
MINNEAPOLIS –October 22, 2012 – Medtronic, Inc. (NYSE: MDT) today announced new findings from the Medtronic CoreValve ADVANCE Study for 1-year survival and health-related quality of life (HRQoL). The findings were presented this week at Transcatheter Cardiovascular Therapeutics (TCT) Meeting 2012 in Miami. Initial 1-year results of the ADVANCE Study revealed that patients experienced high survival rates, with 1-year survival at 82.1 percent and 1-year cardiovascular survival at 88.2 percent. ... 
Download PDFPrinter Friendly Version
10/22/12Medtronic CATALYST™ Mobile Educational Centers Take Spinal Training to Surgeons
MEMPHIS, TENN. - Oct. 22, 2012– Medtronic, Inc. (NYSE: MDT), the world leader in spinal technology, unveiled the CATALYST™ Mobile Educational Centers, a fleet of new, high-tech vehicles that are fully equipped with cutting edge procedural/anatomical labs and conference areas that will bring training and education programs to surgeons and other health care professionals across the United States. The announcement was made during the 27th Annual Meeting of the North American Spine Society (NASS) in... 
Download PDFPrinter Friendly Version
10/22/12Two-Year Follow-Up Of Symplicity Htn-1 Data Confirms Significant And Sustained Blood Pressure Reduction In Expanded Cohort Of Patients
New Data Presented at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium Show Sustained Blood Pressure Reduction(1) and Safety(2) with Symplicity™ Renal Denervation System in Patients with Treatment-Resistant Hypertension MINNEAPOLIS and MIAMI – October 22, 2012 – Medtronic, Inc. (NYSE: MDT) today announced new results from Symplicity HTN-1, the longest running clinical trial investigating the safety and efficacy of renal denervation. These data showed patient... 
Download PDFPrinter Friendly Version
10/18/12Medtronic Announces Approval and Launch of Japan’s First MR-Conditional Pacemaker System
Medtronic Launches Advisa DR MRI™ SureScan™ Pacing System in Japan MINNEAPOLIS – Oct. 18, 2012 – Medtronic, Inc. (NYSE: MDT), today announced the Japanese regulatory approval and launch of the Advisa DR MRI™ SureScan™ pacing system. The Advisa MRI system is the first and only MR-Conditional pacemaker available to patients in Japan, the world’s second largest market for medical devices. With the Advisa MRI system, pacemaker patients will have access to full body scans, without positioning li... 
Download PDFPrinter Friendly Version
10/17/12Medtronic Melody® Transcatheter Pulmonary Valve Receives Prestigious Prix Galien Award
World’s First Transcatheter Valve Honored as “Best Medical Technology” MINNEAPOLIS – October 17, 2012 – Medtronic, Inc.’s (NYSE: MDT) Melody® Transcatheter Pulmonary Valve was awarded the Prix Galien USA 2012 for Best Medical Technology last night. The Prix Galien Award, considered the biomedical industry’s highest accolade and widely recognized as the industry’s equivalent of the Nobel Prize in medicine, recognizes the technical, scientific and clinical research skills and achievements... 
Download PDFPrinter Friendly Version
10/15/12Medtronic Makes Strategic Investment in LifeTech Scientific Corporation
Strategic Alliance to Leverage Best of Both Companies to Reach Cardiovascular Patients in China and other Emerging Markets MINNEAPOLIS and Shenzhen – October 15, 2012 – Medtronic, Inc. (NYSE:MDT) (“Medtronic”) and LifeTech Scientific Corporation (8122:HK) (“LifeTech”) today announced that they have entered into a strategic alliance that brings together the resources and technologies of the world’s largest medical device company with the local market expertise, brand recognition and growth po... 
Download PDFPrinter Friendly Version
10/10/12Covidien Announces Final Results from Landmark DEFINITIVE LE Study in Patients with Peripheral Arterial Disease
Study Confirms Effectiveness of Directional Atherectomy with SilverHawk ™ and TurboHawk ™ Devices as a Frontline Therapy when Treating PAD LAS VEGAS--(BUSINESS WIRE)--Oct. 10, 2012-- Covidien (NYSE:COV), a leading global provider of healthcare products, today announced final 12-month results from its DEFINITIVE LE (Determination of Effectiveness of SilverHawk™ / TurboHawk™ Peripheral Plaque Excision Systems for the Treatment of ... 
 Printer Friendly Version
10/08/12Medtronic Launches BRYAN® Cervical Disc with ACD Instrument Set
Offering Surgeons in the United States a New Procedure to implant the BRYAN® Cervical Disc System MEMPHIS, TENN. – October 8, 2012 – Medtronic, Inc. (NYSE: MDT) today announced it has initiated the commercial introduction in the United States of the ACD Instrument Set, a brand new set of instruments that can be used to insert the clinically proven BRYAN® Cervical Disc.  The BRYAN® Disc was FDA approved in 2009 for the treatment of single-level cervical disc disease (radiculopa... 
Download PDFPrinter Friendly Version
10/05/12Medtronic Launches New Angioplasty Catheter for Below-the-Knee Arteries
Medtronic Launches New Angioplasty Catheter for Below-the-Knee Arteries Newly Approved Medical Device Expands Company’s Growing Portfolio of Products Used to Treat Peripheral Artery Disease MINNEAPOLIS –– October 5, 2012 –– With a focus on developing lesion specific solutions for peripheral artery disease, Medtronic, Inc. (NYSE: MDT) today announced the U.S. and international launches of the Amphirion Plus Percutaneous Transluminal Angioplasty (PTA) Catheter for the interventional treatment... 
Download PDFPrinter Friendly Version
10/05/12Medtronic Completes Enrollment in Landmark Study of IN.PACT Drug-Eluting Balloon in Peripheral Artery Disease
Medtronic Completes Enrollment in Landmark Study of IN.PACT Drug-Eluting Balloon in Peripheral Artery Disease Largest Randomized Controlled Trial of Its Kind, IN.PACT DEEP Evaluates Safety and Effectiveness of Novel Treatment for Critical Limb Ischemia Below the Knee MINNEAPOLIS –– October 5, 2012 –– Committed to researching treatments for peripheral artery disease, Medtronic, Inc. (NYSE: MDT) today announced that patient enrollment in a landmark study of its IN.PACT Amphirion drug-eluting ... 
Download PDFPrinter Friendly Version
10/04/12New Study Demonstrates Superior Clinical and Quality of Life Benefits of Medtronic Sacral Neuromodulation Compared to Standard Medical Treatment for Overactive Bladder at Six Months
InSite Study Results Show Efficacy and Quality of Life Advantages with InterStim® System MINNEAPOLIS – October 4, 2012 – The first-ever study to compare the clinical benefits of Medtronic, Inc. (NYSE: MDT) sacral neuromodulation (SNM) with standard medical treatment (oral medication) in less-severe overactive bladder (OAB) patients – defined as those failing at least one previous OAB medication – found SNM, delivered by the Medtronic InterStim® system, to be associated with superior efficacy... 
Download PDFPrinter Friendly Version
10/04/12Covidien Announces FDA 510(k) Clearance and CE Mark for Nellcor™ Bedside Respiratory Patient Monitoring System
New system completes enhancement of entire pulse oximetry bedside monitoring portfolio BOULDER, Colo.--(BUSINESS WIRE)--Oct. 4, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, today announced U.S. Food and Drug Administration 510(k) clearance and European Economic Area (EEA) CE Mark approval for the Covidien Nellcor™ Bedside Respi... 
 Printer Friendly Version
10/03/12Medtronic Completes First-In-Man Study for Investigational Next-Generation Multi-Electrode Renal Denervation System in Patients with Treatment-Resistant Hypertension
Multi-Electrode Radiofrequency Renal Denervation System Builds on Experience with the Symplicity™ Renal Denervation System MINNEAPOLIS – October 3, 2012 – Medtronic, Inc. (NYSE: MDT) announced today that it has successfully completed the first phase of the feasibility study of its next-generation renal denervation system featuring a simultaneously firing multi-electrode catheter and advanced radio-frequency (RF) generator. A total of nine patients were treated with a 100 percent acute succes... 
Download PDFPrinter Friendly Version
10/03/12Medtronic Extends Sponsorship of Twin Cities Marathon, TC 10 Mile and Affiliated Youth Events
Strong Partnership in Promoting Healthy Lifestyles Continues for Three Additional Years MINNEAPOLIS – October 3, 2012 –Medtronic and Twin Cities In Motion, the organizers of the Medtronic Twin Cities Marathon, today announced a three-year agreement that will keep Medtronic as the title sponsor of four premier Twin Cities In Motion events: TC 1 Mile, TC Family Events, TC 10 Mile, and the Twin Cities Marathon.  Additionally, Medtronic will continue to support the Medtronic TC Kids Maratho... 
Download PDFPrinter Friendly Version
10/03/12Covidien plc to Report Fourth-Quarter Results on November 9, 2012
DUBLIN--(BUSINESS WIRE)--Oct. 3, 2012-- Covidien plc (NYSE: COV) will report fourth-quarter results on November 9, 2012, before trading begins. The Company will hold a conference call for investors at 8:30 a.m. ET. The call can be accessed in the following ways: At Covidien’s website: http://investor.covidien.com By telephone: For both “listen-only” participants and those participants who wish to ta... 
 Printer Friendly Version
10/02/12New Data Reinforce Positive Clinical Outcomes for Direct Aortic Implants Using the Medtronic CoreValve System
Medtronic Launches New European Clinical Study to Further Evaluate Direct Aortic Surgical Approach MINNEAPOLIS – October 2, 2012 – Medtronic, Inc. (NYSE: MDT) today reported two clinical research updates related to the Medtronic CoreValve® System direct aortic implantation approach, which received CE (Conformité Européenne) Mark in November 2011 for patients with severe aortic stenosis. New data presented at the PCR London Valves 2012 Meeting confirm that direct aortic implantation of the ... 
Download PDFPrinter Friendly Version
10/02/12Mallinckrodt Completes Acquisition of CNS Therapeutics, Inc.
HAZELWOOD, Mo.--(BUSINESS WIRE)--Oct. 2, 2012-- Mallinckrodt, the Pharmaceuticals business of Covidien (NYSE: COV), today announced that it has completed its acquisition of CNS Therapeutics, Inc. for approximately $100 million. CNS is a privately held specialty pharmaceuticals company focused on developing and commercializing products for site-specific administration to the central nervous system to treat neurological disorders and intractable... 
 Printer Friendly Version
10/01/12Medtronic Initiates First Clinical Trial of the Symplicity™ Renal Denervation System for Treatment-Resistant Hypertension in Japan
MINNEAPOLIS – October 1, 2012 – Medtronic, Inc., (NYSE: MDT), announced today the start of Symplicity HTN-Japan, the first clinical trial with the Symplicity™ renal denervation system in Japan for patients with treatment- resistant hypertension. The clinical trial is an open-label study that will randomize subjects 1:1 to renal denervation vs. no denervation with both groups receiving maximal tolerated doses of anti-hypertensive medications. The clinical trial is being conducted in approximately... 
Download PDFPrinter Friendly Version
10/01/12Covidien Unveils Sonicision™ Cordless Ultrasonic Dissection Device and iDrive™ Ultra Powered Stapling System at 2012 American College of Surgeons Clinical Congress
New cordless instruments offer surgeons increased freedom to move and position devices, allowing for greater precision in the operating room Sonicision is the medical industry’s first cordless ultrasonic device for bariatric, colorectal, gynecological, urological and general surgical procedures CHICAGO--(BUSINESS WIRE)--Oct. 1, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, will showcase s... 
 Printer Friendly Version
09/27/12Medtronic Signs Agreement to Acquire China Kanghui Holdings
Acquisition Advances Medtronic’s Globalization Strategy; Provides Strong Local China Operation as well as Broader Orthopedics Participation MINNEAPOLIS and CHANGZHOU, CHINA – Sept. 27, 2012 – Medtronic, Inc. (NYSE: MDT) and China Kanghui Holdings (NYSE: KH) announced today that they have entered into a merger agreement whereby Medtronic will acquire Kanghui.  The agreement calls for Medtronic to pay approximately $816 million in cash ($30.75 per American depository share).  The tot... 
Download PDFPrinter Friendly Version
09/26/12Medtronic Gains CE Mark for CoreValve® Evolut™ 23mm
CoreValve Evolut Designed for Optimal Fit; With 23mm the CoreValve Family Treats Broadest Range of Patient Valve Sizes MINNEAPOLIS – September 26, 2012 – Medtronic, Inc. (NYSE: MDT) today announced it has received CE (Conformité Européenne) Mark for its Medtronic CoreValve® Evolut™ 23mm valve, its latest self-expanding transcatheter aortic valve implantation (TAVI) system. The new valve incorporates technology that optimizes fit, thereby promoting sealing between the prosthetic valve and the... 
Download PDFPrinter Friendly Version
09/25/12Mallinckrodt Joins The Partnership at Drugfree.org to Launch The Medicine Abuse Project
ST. LOUIS--(BUSINESS WIRE)--Sep. 25, 2012-- Mallinckrodt, the pharmaceuticals business of Covidien (NYSE: COV), today joined The Partnership at Drugfree.org in launching The Medicine Abuse Project, a multi-year effort to raise awareness and curb the abuse of prescription medicine by teens and young adults. Beginning this week, the campaign aims to prevent half a million teens from abusing such medications over the next five years. ... 
 Printer Friendly Version
09/24/12Medtronic Gains CE Mark for New Oxygenation System for Adult Cardiac Surgery
New System Designed for Patient Safety, Ease of Use During Open-Heart Procedures MINNEAPOLIS – September 24, 2012 – Medtronic, Inc. (NYSE: MDT) today announced Conformité Européenne (CE) Mark for its new Affinity Fusion® oxygenation system in Europe. This system, which is designed to serve as a patient’s lungs by oxygenating and removing carbon dioxide from blood during various open-heart surgical procedures, incorporates numerous innovations for patient safety and ease of use. Notably, syst... 
Download PDFPrinter Friendly Version
09/24/12Mallinckrodt Announces Definitive Agreement to Acquire CNS Therapeutics, Inc.
HAZELWOOD, Mo.--(BUSINESS WIRE)--Sep. 24, 2012-- Mallinckrodt, the Pharmaceuticals business of Covidien (NYSE: COV), today announced a definitive agreement to acquire CNS Therapeutics, Inc., a privately held specialty pharmaceutical company focused on developing and commercializing products for site-specific administration to the central nervous system to treat neurological disorders and intractable chronic pain. Mallinckrodt will a... 
 Printer Friendly Version
09/21/12Medtronic Commits $6 Million to Address Cardiovascular Disease, Diabetes Care for Underserved in India
Building on More Than $1.2 Million in Health-Related Grants Already Awarded in India, the Medtronic Foundation Will Increase Annual Funding to Help Expand Access to Care. MINNEAPOLIS – September 21, 2012 – One year after the historic United Nations High Level Meeting on Noncommunicable diseases (NCDs), Medtronic today announced a five-year, $6 million (U.S.) philanthropic commitment in India to accelerate programs specifically designed to expand access to quality care and management of diabe... 
Download PDFPrinter Friendly Version
09/21/12Medtronic Elects Preetha Reddy to the Board of Directors
MINNEAPOLIS –– Sept. 21, 2012 –– Medtronic, Inc. (NYSE: MDT) today announced that its Board of Directors unanimously voted to elect Preetha Reddy, managing director of Apollo Hospitals Enterprise Limited, a division of the Apollo Group, which is one of the largest hospital groups in Asia, to the board as an independent director. In addition to her work as the managing director of Apollo Hospitals, Ms. Reddy has been prominent in industry and Indian government efforts to advance important health... 
Download PDFPrinter Friendly Version
09/20/12Medtronic Announces First Patient Enrollment in Global Heart Rhythm Study
IMPROVE Brady Study Aims to Improve Adoption of Treatment Guidelines in Emerging Markets MINNEAPOLIS – September 20, 2012 – Medtronic, Inc. (NYSE: MDT) today announced the first patient enrollment in the IMPROVE Brady (Registry to Improve the Adoption of Consensus Treatment Guidelines) clinical trial, which will evaluate the impact of physician-led improvement initiatives on the diagnosis and treatment of patients with a common abnormal heart rhythm (sinus node dysfunction). During the study... 
Download PDFPrinter Friendly Version
09/20/12Covidien Announces Dividend Increase of 16%
DUBLIN--(BUSINESS WIRE)--Sep. 20, 2012-- Covidien plc (NYSE: COV) today announced that its Board of Directors has declared a 16% increase in the quarterly dividend rate, from $0.225 per ordinary share to $0.26 per ordinary share. “This increase reflects our good performance to date in 2012, our commitment to enhance shareholder value and the Board’s confidence in our future growth prospects,” said José (Joe) E. Almeida, Chairman, ... 
 Printer Friendly Version
09/17/12Covidien Expands Device Portfolio for Endovascular Treatment of Peripheral Vascular Disease
Viance™ Crossing Catheter and Enteer™ Re-entry System offer new approach to chronic total occlusions in peripheral arteries PLYMOUTH, Minn.--(BUSINESS WIRE)--Sep. 17, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the launch of the Viance™ Crossing Catheter and Enteer™ Re-entry System for treating chronic total occlusions (CTOs) endovascularly. The devices are now available in the United ... 
 Printer Friendly Version
09/14/12HeartWare Presentation at the UBS Global Life Sciences Conference to be Webcast
FRAMINGHAM, Mass. and SYDNEY, Sept. 14, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the UBS Global Life Sciences Conference at 8:00 a.m. EDT on Wednesday, September 19, 2012.  The conference is being held September 19-20, 2012 at the G... 
 Printer Friendly Version
09/13/12Covidien Announces Highlights from Investor Meeting
NEW YORK--(BUSINESS WIRE)--Sep. 13, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today outlined the initiatives, strategies and innovations that are expected to drive the Company’s growth in 2013 and beyond at a meeting held here for the investment community. Chairman, President and CEO José (Joe) E. Almeida spoke about Covidien’s recent accomplishments, the current market environment for medical ... 
 Printer Friendly Version
09/13/12Medtronic Named a World Leader in Sustainability
MINNEAPOLIS – Sept. 13, 2012 – Medtronic, Inc. (NYSE: MDT) today was named one of the world’s leading sustainability companies by its inclusion in the Dow Jones Sustainability World Index (DJSI World) and the FTSE4Good Index Series. The DJSI list, released today, analyzes companies on a series of sustainability criteria, including economic performance, environmental stewardship and social responsibility. “We are proud of our efforts to address chronic disease, to follow environmentally sound b... 
Download PDFPrinter Friendly Version
09/12/12Health-Economic Analysis Suggests Medtronic Symplicity™ Renal Denervation System Is Cost-Effective and May Reduce Cardiovascular Event Risks for Patients with Treatment-Resistant Hypertension
Findings Published in The Journal of the American College of Cardiology Suggest Renal Denervation Could Substantially Reduce Cardiovascular Morbidity and Mortality for Patients with a Condition that Affects 120 Million People MINNEAPOLIS – September 12, 2012 – Medtronic, Inc. (NYSE: MDT) today announced findings from a health-economic analysis published online before print in The Journal of the American College of Cardiology that suggest the Symplicity™ renal denervation system is a cost-eff... 
Download PDFPrinter Friendly Version
09/12/12Medtronic CFO Gary Ellis to Speak at UBS Global Lifesciences Conference
MINNEAPOLIS – Sept 12, 2012 – Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the UBS Global Life Sciences Conference on Wednesday, September 19, 2012, in New York. Gary Ellis, senior vice president and chief financial officer of Medtronic, will make a presentation about Medtronic beginning at 2:30 p.m. ET (1:30 p.m. CT). A live audio webcast of the presentation will be available on September 19, 2012 by clicking on the Inves... 
Download PDFPrinter Friendly Version
09/11/12Covidien Announces FDA 510(k) Clearance of LigaSure™ Small Jaw Instrument for Ear, Nose and Throat Surgical Procedures
Expanded indication for small jaw device provides valuable, multifunctional tool for head and neck surgeons BOULDER, Colo.--(BUSINESS WIRE)--Sep. 11, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the LigaSure™ curved, small jaw, open sealer/divider surgical instrument to be used in ear, nose... 
 Printer Friendly Version
09/06/12Medtronic Releases 2012 Corporate Citizenship Report
“Contributing to a Healthier Future” Reviews Company’s Economic, Social and Environmental Performance for Fiscal Year 2012 MINNEAPOLIS – Sept. 6, 2012 – Medtronic, Inc. (NYSE:MDT) has released the company’s 2012 Corporate Citizenship Report, “Contributing to a Healthier Future” at www.medtronic.com/2012citizenshipreport. In addition to providing information and key metrics on Medtronic’s economic, social and environmental performance, the report communicates the company’s priorities, goals an... 
Download PDFPrinter Friendly Version
09/06/12Medtronic CFO Gary Ellis to Speak at Morgan Stanley Global Healthcare Conference
MINNEAPOLIS – Sept 6, 2012 – Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Morgan Stanley Global Healthcare Conference on Tuesday, September 11, 2012, in New York. Gary Ellis, senior vice president and chief financial officer of Medtronic, will make a presentation about Medtronic beginning at 9:45 a.m. ET (8:45 a.m. CT). A live audio webcast of the presentation will be available on September 11, 2012 by clicking on the ... 
Download PDFPrinter Friendly Version
09/04/12Bayer’s New CONTOUR® NEXT LINK Blood Glucose Meter Now Available with Compatible Medtronic Insulin Pumps
Medtronic, Inc. (NYSE: MDT) and Bayer HealthCare today announced that Bayer’s CONTOUR® NEXT LINK, a new blood glucose meter, is now available in the U.S. with Medtronic’s compatible integrated diabetes management systems. Bayer’s new meter provides exceptional accuracy utilizing high-performance CONTOUR® NEXT test strips, helping optimize insulin delivery through wireless communication with the MiniMed® Paradigm™ REAL-Time Revel™ insulin pump and the MiniMed Paradigm Real Time Insulin pump. Pe... 
Download PDFPrinter Friendly Version
08/30/12Landmark IMPROVE HF Trial Shows Evidence-Based Programs Result in Improvements in Heart Failure Patients Regardless of Race, and Improves Survival
Medtronic-Supported Study is one of First to Evaluate Improvements, by Race, in the Use of Heart Failure Therapies in the Outpatient Setting MINNEAPOLIS – August 30, 2012 – Medtronic, Inc. (NYSE: MDT) today announced new findings from the landmark IMPROVE HF (Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting) trial, which showed equivalent improvements in the care of heart failure patients across all races and ethnicities when evidence-based, perfo... 
Download PDFPrinter Friendly Version
08/30/12Covidien Announces Investor Meeting Agenda
DUBLIN--(BUSINESS WIRE)--Aug. 30, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the agenda for its investor meeting on Thursday, September 13, 2012. The event will be held at Cipriani, 55 Wall Street, New York, NY. A webcast of the presentations will begin at 1:40 pm ET and the webcast will conclude by 5:00 pm ET. The program will include presentations by Covidien's Chairman, President ... 
 Printer Friendly Version
08/29/12Medtronic Completes High Risk Patient Enrollment in CoreValve® U.S. Pivotal Trial and Gains FDA Approval to Study Intermediate Risk Patients in Global SURTAVI Trial
MINNEAPOLIS – August 29, 2012 – Medtronic, Inc. (NYSE: MDT) has reached two clinical program milestones for its CoreValve® System in the United States. First, it completed enrollment in its study of high risk patients in its CoreValve® U.S. Pivotal Trial, which concludes the total Trial enrollment of more than 1,500 patients with severe aortic stenosis who are at high or extreme risk for aortic valve surgery. Medtronic continues to enroll extreme risk patients in the Trial as part of the U.S. Fo... 
Download PDFPrinter Friendly Version
08/28/12Medtronic Launches Resolute Integrity Coronary Stent System in Japan
Part of Global Clinical Program, RESOLUTE Japan Study Supported Novel Heart Device’s Regulatory and Reimbursement Approvals in World’s Second Largest Med-Tech Market MINNEAPOLIS –– August 28, 2012 –– Expanding global access to proven cardiovascular treatment options, Medtronic, Inc. (NYSE: MDT) announced today the launch of the Resolute Integrity™ Coronary Stent System in Japan, the world’s second largest market for medical devices. Indicated for the treatment of coronary artery disease, the... 
Download PDFPrinter Friendly Version
08/28/12Covidien Receives FDA 510(k) Clearance for Groundbreaking iDrive™ Ultra Powered Stapling System
World’s only fully powered reusable surgical EndoStapling platform sets new standards in precision during surgery NEW HAVEN, Conn.--(BUSINESS WIRE)--Aug. 28, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, announced today that it has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the iDrive™ Ultra powered stapling system. The new stapling system is the only fully powered, r... 
 Printer Friendly Version
08/27/12Medtronic Establishes Shanghai Innovation Center
Facility to support R&D in China SHANGHAI, CHINA – August 28, 2012 – Medtronic, the global medical technology leader, announced today the official opening of its Innovation Center in Shanghai, China. The new facility, located in the company’s China headquarters and the first outside the U.S. and Europe, represents the company’s initial step in creating local product research and development in China. “Globalization is a key strategy and driver of growth ... 
Download PDFPrinter Friendly Version
08/27/12Five-Year Analysis of Pivotal REVERSE Trial Demonstrates Long-Term Clinical Benefits of Medtronic CRT-D Therapy in Mild Heart Failure Patients
Low Mortality and Heart Failure Hospitalization Sustained at 5-Years Post Implant with Medtronic CRT-D Devices MUNICH, GERMANY – August 27, 2012 – Medtronic, Inc. (NYSE: MDT) today announced findings from a new clinical analysis of the pivotal REVERSE (Resynchronization Reverse Remodeling in Systolic Left Ventricular Dysfunction) trial, which demonstrated that its cardiac resynchronization therapy (CRT) devices are associated with low mortality and heart failure hospitalization rates over 5 ye... 
Download PDFPrinter Friendly Version
08/27/12Medtronic Study Confirms Long-Term Safety of Drug-Eluting Coronary Stents
MINNEAPOLIS and MUNICH –– August 27, 2012 –– Results of a landmark clinical trial, PROTECT, presented for the first time today at the 2012 European Society of Cardiology (ESC) Congress, confirm the long-term safety of drug-eluting stents in the treatment of coronary artery disease in real-world clinical practice. Dr. William Wijns, one of the study’s co-principal investigators, presented the findings at ESC 2012 as part of a late-breaking clinical trials session. The results of PROTECT –– the l... 
Download PDFPrinter Friendly Version
08/27/12FDA Approves Mallinckrodt’s EXALGO® (hydromorphone HCl) Extended-Release Tablets 32 mg (CII) for Opioid-Tolerant Patients with Moderate-to-Severe Chronic Pain
ST. LOUIS--(BUSINESS WIRE)--Aug. 27, 2012-- The U.S. Food and Drug Administration (FDA) has notified Mallinckrodt, the pharmaceuticals business of Covidien (NYSE:COV), that it has approved a 32 mg tablet strength of EXALGO® (hydromorphone HCI) Extended-Release Tablets (CII) for opioid-tolerant patients with moderate-to-severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended period of time. The FDA approved the 8, ... 
 Printer Friendly Version
08/26/12Randomized Clinical Trial Data Show Medtronic Symplicity™ Renal Denervation System Continues to Demonstrate Significant Blood Pressure Reduction in All Treatment Groups
18-Month Update from the Symplicity HTN-2 Randomized Clinical Trial Presented at ESC Congress 2012 MINNEAPOLIS and MUNICH – August 26, 2012 – Medtronic, Inc. (NYSE: MDT) today announced new results from Symplicity HTN-2 the only randomized clinical trial investigating safety and efficacy of renal denervation. The 18-month data presented for the first time today at the European Society of Cardiology (ESC) Congress 2012 showed the Symplicity system continues to provide superior and sustained blo... 
Download PDFPrinter Friendly Version
08/24/12Medtronic Receives FDA Approval, CE Mark for Arctic Front Advance™ Cardiac Cryoballoon to Treat Atrial Fibrillation
Next-Generation Technology Reinforces Safety and Efficacy While Improving Procedure Efficiency MINNEAPOLIS – Aug. 24, 2012 – Medtronic, Inc. (NYSE:MDT) today announced that its Arctic Front Advance™ Cardiac Cryoballoon has received both U.S. Food and Drug Administration (FDA) approval and CE (Conformité Européenne) Mark for the treatment of paroxysmal atrial fibrillation (PAF). With the only cryoballoon system currently on the market worldwide, Medtronic’s second-generation system provides a m... 
Download PDFPrinter Friendly Version
08/23/12Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2013
MINNEAPOLIS – August 23, 2012 – The board of directors of Medtronic, Inc. (NYSE:MDT) today approved a cash dividend of $0.26 per share of the company’s common stock. The quarterly dividend represents a 7 percent increase over the prior year. The dividend is payable on October 26, 2012, to shareholders of record at the close of business on October 5, 2012. Medtronic, a constituent of the S&P 500 Dividend Aristocrat index, has committed to returning 50 percent of its free cash flow to sharehol... 
Download PDFPrinter Friendly Version
08/23/12Mallinckrodt Announces Agreement with Xanodyne to Purchase Roxicodone®
HAZELWOOD, Mo.--(BUSINESS WIRE)--Aug. 23, 2012-- Mallinckrodt, the Pharmaceuticals business of Covidien (NYSE: COV), today announced that it has entered into an agreement with Xanodyne Pharmaceuticals to purchase Roxicodone® (oxycodone hydrochloride tablets USP) in 5, 15 and 30 mg dosage strengths. Roxicodone, currently marketed in the United States, is an immediate release formulation of oxycodone indicated for the management of moderate to sever... 
 Printer Friendly Version
08/22/12Covidien Conducts Voluntary Recall and Discontinues Duet TRS™ Reload
MANSFIELD, Mass.--(BUSINESS WIRE)--Aug. 22, 2012-- Covidien today announced that it is conducting a voluntary recall of all production lots for the Duet TRS™ Universal Straight and Articulating Single-Use Loading Units (SULU). In addition, the Company has discontinued manufacturing the Duet TRS Universal Straight and Articulating SULU. Covidien has received one report that links the Duet TRS tissue reinforcement material to a post-oper... 
 Printer Friendly Version
08/21/12Medtronic Reports First Quarter Earnings
Revenue of $4.0 Billion Grew 5% on a Constant Currency Basis; 2% as Reported GAAP and Non-GAAP Diluted EPS Growth of 8% Free Cash Flow of $ 1.2 Billion, GAAP Cash Flow from Operations of $1.3 Billion MINNEAPOLIS – August 21, 2012 – Medtronic, Inc. (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2013, which ended July 27, 2012. The Company reported worldwide first quarter revenue of $4.008 billion, an increase of 5 percent on a constant currency basis afte... 
Download PDFPrinter Friendly Version
08/20/12Medtronic Announces CE Mark of Viva/Brava Cardiac Resynchronization Therapy Devices
New Devices Automatically Adapt to Patient Needs and Continuously Optimize CRT, Improving Response Rate to Lifesaving Therapy MINNEAPOLIS – August 20, 2012 – Medtronic, Inc. today announced it has received CE (Conformité Européenne) Mark of its Viva®/Brava® portfolio of cardiac resynchronization therapy with defibrillation (CRT-D) devices. The family of CRT-Ds features a new algorithm, called AdaptivCRT®, which significantly improves heart failure patients’ response rate to CRT-D therapy, as c... 
Download PDFPrinter Friendly Version
08/20/12Covidien Initiates a Voluntary Recall of DGPHP RFA High-Power Single Use Grounding Pads and Cool-tip™ RFA Electrode Kits that Contain DGPHP RFA High-Power Single Use Grounding Pads
MANSFIELD, MA – August 17, 2012 -- Covidien today announced that it is conducting a voluntary recall of certain production lots of the DGPHP RFA High-Power Single Use Grounding Pads and Cool-tip™ RFA Electrode Kits that contain DGPHP RFA High-Power Single Use Grounding Pads. Covidien has voluntarily decided to recall specific lots manufactured prior to August 30, 2011, due to the potential degradation of foil within the DGPHP grounding pad.  Covidien has received reports o... 
 Printer Friendly Version
08/14/12Medtronic Launches CareLink Express™ Service
Pilot Shows New Remote Monitoring Service Allows Quick Access to Care for Patients MINNEAPOLIS – August 14, 2012 – In line with the Company’s commitment to provide superior economic value to customers, Medtronic, Inc. (NYSE: MDT), today announced the U.S. launch of the CareLink Express™ Service.  This service is a remote monitoring system that enables clinicians in healthcare facilities to quickly obtain data regarding the status of Medtronic implanted cardiac devices, facilitating faster... 
Download PDFPrinter Friendly Version
08/14/12Covidien Announces Its Support for The Joint Commission’s Sentinel Event Alert Recommendations on the “Safe use of opioids in hospitals”
BOULDER, Colo.--(BUSINESS WIRE)--Aug. 14, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, today announced its support for The Joint Commission’s recent Sentinel Alert recommendations for the “Safe use of opioids in hospitals.” Opioids, frequently given to patients for pain management, may be associated with increased risk f... 
 Printer Friendly Version
08/10/12Medtronic to Webcast Annual Shareholder Meeting
MINNEAPOLIS – Aug. 10, 2012 - Medtronic investors and other interested parties are invited to participate in a live video webcast of the Medtronic Annual Shareholder Meeting on Thursday, August 23, 2012, at 10:30 a.m. Central Time. The webcast can be accessed by clicking on the Investor section link through the Medtronic website at www.medtronic.com on Thursday, August 23, 2012. Within 24 hours of the webcast, a replay and a transcript of the prepared remarks will be available under the Events... 
Download PDFPrinter Friendly Version
08/10/12HeartWare Presentation At The Canaccord Genuity 32nd Annual Growth Conference To Be Webcast
FRAMINGHAM, Mass. and SYDNEY, Aug. 10, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Canaccord Genuity 32nd Annual Growth Conference at 8:00 a.m. EDT on Wednesday, August 15, 2012.  The conference is being held August 14-16, 2012 at ... 
 Printer Friendly Version
08/09/12Medtronic to Announce Financial Results for Its First Quarter of Fiscal Year 2013
MINNEAPOLIS – Aug. 9, 2012 – Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the first quarter of its fiscal year 2013 on Tuesday, August 21, 2012. A news release will be issued at approximately 6:15 a.m. Central Time and will be available at www.medtronic.com/newsroom. The earnings news release will include summary financial information for Medtronic’s first quarter which ended July 27, 2012. Medtronic will host a webcast at 7 a.m. Central Time to discuss finan... 
Download PDFPrinter Friendly Version
08/09/12HeartWare Presentation at the 2012 Wedbush PacGrow Lifesciences Management Access Conference to be Webcast
FRAMINGHAM, Mass. and SYDNEY, Aug. 9, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference at 9:10 a.m. EDT on Tuesday, August 14, 2012.  The conference is being held August 1... 
 Printer Friendly Version
08/07/12HeartWare Reports Second Quarter 2012 Results
- Revenue increased 42% to $29.1 million in second quarter of 2012 on strength of international market penetration - - Increased investment as Company prepares for new clinical programs and expanded commercialization - - Conference call today at 5:00 p.m. U.S. E.T. - FRAMINGHAM, Mass. and SYDNEY, Aug. 7, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizi... 
 Printer Friendly Version
08/06/12Covidien to Host Investor Meeting on September 13, 2012
DUBLIN--(BUSINESS WIRE)--Aug. 6, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, will host an investor meeting on Thursday, September 13, 2012, to update the investment community on the Company and its growth initiatives, strategic priorities and financial outlook. The event, held at Cipriani, 55 Wall Street, New York, NY, will begin around noon and is expected to conclude by 5:00 p.m. The program ... 
 Printer Friendly Version
08/04/12Covidien Implements a Voluntary Recall of Certain Lots of Shiley™ Adult Tracheostomy Tubes
  BOULDER, CO – August 4, 2012-- Covidien today announced that it notified customers on July 18, 2012, about a voluntary global recall of certain lots of its Shiley™ reusable cannula, cuffed adult tracheostomy tubes, size 8. This action was in response to reports of volume leakage and/or disconnection between the inner and outer cannulae. Customers are instructed to return all Shiley 8LPC and 8FEN tracheostomy tubes from the affected lots. If one of the recalled tube... 
 Printer Friendly Version
08/02/12HeartWare Completes Acquisition Of World Heart Corporation
FRAMINGHAM, Mass. and SALT LAKE CITY, Aug. 2, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR, ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced the closing of the acquisition of World Heart Corporation following the approval of the transaction today by World Heart stockholders. Under the terms of the merger agreement, HeartWare acqui... 
 Printer Friendly Version
08/02/12Covidien Opens US$45 Million R&D Facility in China
New center to spur medical innovation in China and across Emerging Markets SHANGHAI--(BUSINESS WIRE)--Aug. 2, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the official opening of its China Technology Center (CTC) Research and Development (R&D) facility in Shanghai. “Establishing this R&D facility in Shanghai reinforces Covidien’s continued commitment to providing innovati... 
 Printer Friendly Version
07/30/12Medtronic Announces 510(k) Clearance of Bipolar Sealer with Cutting for Orthopaedic Surgery
MINNEAPOLIS – July 30, 2012 – Medtronic, Inc. (NYSE: MDT) announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for the Aquamantys®3 BSC 9.1S Bipolar Sealer with Cutting, a new addition to the orthopaedic portfolio of the company’s Advanced Energy business. The BSC 9.1S Bipolar Sealer with Cutting gives surgeons the ability to optimize efficiency in surgical cases by combining hemostatic sealing capabilities for soft tissue and bone and monopolar cut... 
Download PDFPrinter Friendly Version
07/30/12Covidien Announces FDA 510(k) Clearance of the Nellcor™ Bedside SpO2 Patient Monitoring System
Enhanced Features Enable Rapid Clinician Response to Subtle yet Critical Heart Rate and Oxygen Saturation (SpO2) Changes BOULDER, Colo.--(BUSINESS WIRE)--Jul. 30, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care solutions, today announced the U.S. Food and Drug Administration (FDA) has granted the Company 510(k) clearance to market the Covidien Nellcor™ Bedside SpO2 Patient Monitoring System. The n... 
 Printer Friendly Version
07/30/12HeartWare Schedules Second Quarter Conference Call And Webcast
FRAMINGHAM, Mass. and SYDNEY, July 30, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three months ended June 30, 2012, at 5:00 p.m. U.S. Eastern Daylight Time on Tuesday, August 7, 2012 (being 7:00 a.m. Australian Eastern Standard Time, on August 8, 2012). The Company plans to release the financial results prior to the conference call. The conference call with management wi... 
 Printer Friendly Version
07/26/12Covidien Reports Third-Quarter Results
View PDF Net sales up 3% (operational growth 6%); Medical Devices sales up 4% (operational growth 8%) Third-quarter diluted GAAP earnings per share from continuing operations were $0.93; excluding specified items, adjusted diluted earnings per share from continuing operations were $1.07, up 6% DUBLIN--(BUSINESS WIRE)--Jul. 26, 2012-- Covidien plc (NYSE: COV) today reported results for the third quarter of fiscal 2012 (April - June 2012). Third-quarter net sales of $3.01 billion increased... 
 Printer Friendly Version
07/23/12Medtronic Announces 2012 “Global Heroes”
Distance Runners from Around the World Who Benefit from Medical Technology to Run Medtronic Twin Cities Marathon Events this Fall MINNEAPOLIS – July 23, 2012– Twenty-five long-distance runners who benefit from medical technology will be honored as “Medtronic Global Heroes” when they run the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile on Sunday, October 7, 2012. This year’s team includes 10 international runners, the most in the program’s seven-year history.  Countries represe... 
Download PDFPrinter Friendly Version
07/19/12Medtronic Expands Option for the CD Horizon® Solera™ System
MEMPHIS, TENN., – July 19, 2012 – Medtronic, Inc. (NYSE: MDT) today announced the initiation of the global launch of the CD HORIZON® SOLERA™ 5.5/6.0 System. This product launch is part of the CD HORIZON® family of fixation devices, designed to provide spinal stabilization and correction as an adjunct to fusion in patients suffering from painful and function-limiting disorders of the middle and lower back. The CD HORIZON® SOLERA™ 5.5/6.0 System extends the capability of the CD HORIZON® SOLERA™ 4... 
Download PDFPrinter Friendly Version
07/18/12Medtronic Begins Global Clinical Trial Evaluating CoreValve® System Implantation in Intermediate-Risk Patients
MINNEAPOLIS – July 18, 2012 – Medtronic, Inc. (NYSE: MDT) today announced the first patient enrollment in a global, multicenter, randomized clinical trial comparing the Medtronic CoreValve® System with surgical aortic valve replacement in patients with severe aortic stenosis who are at intermediate risk to undergo open-heart surgery. The trial, called Medtronic CoreValve Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial, will evaluate the potential for the minimall... 
Download PDFPrinter Friendly Version
07/18/12Medtronic Foundation Announces New Heartrescue Project Partnerships
Partners Join Five Others in Challenge to Improve Sudden Cardiac Arrest Survival by 50 Percent Over Five Years in Their Geographies MINNEAPOLIS –– July 18, 2012 –– The Medtronic Foundation has awarded $3.75 million in grants to two new partners – the Illinois HeartRescue Collaborative through the University of Illinois and American Medical Response (AMR) – to improve sudden cardiac arrest survival rates in Illinois and in select communities served by AMR in the next five years. The new partne... 
Download PDFPrinter Friendly Version
07/18/12Covidien Declares Quarterly Cash Dividend
DUBLIN--(BUSINESS WIRE)--Jul. 18, 2012-- Covidien plc (NYSE: COV) today announced that its Board of Directors has declared a quarterly cash dividend of $0.225 per ordinary share. The dividend is payable on August 16, 2012, to shareholders of record on July 30, 2012. ABOUT COVIDIEN Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers va... 
 Printer Friendly Version
07/12/12Covidien Announces New Bipolar Resection Software Application for ForceTriad™ Energy Platform
Latest software introduces new capability and expands use to additional procedures BOULDER, Colo.--(BUSINESS WIRE)--Jul. 12, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the North American introduction of a new bipolar resection in saline software application for its ForceTriad™ energy platform. With this new application, surgeons may now perform transurethral resections of the prostate ... 
 Printer Friendly Version
07/11/12FDA Expands Clearance of Medtronic Implants for the Treatment of Snoring
New labeling means more patients can get relief from snoring MINNEAPOLIS – July 11, 2012 – Medtronic, Inc. (NYSE: MDT) today announced that the FDA has cleared new labeling information for the Pillar Palatal Implant system which is used to help reduce the severity of snoring in patients. While the Medtronic device had been previously approved for the treatment of snoring and sleep apnea, this latest  approval allows ENT surgeons to use up to five Pillar Implants specifically for snoring -... 
Download PDFPrinter Friendly Version
07/09/12HeartWare Names Peter F. McAree Chief Financial Officer
FRAMINGHAM, Mass. and SYDNEY, July 9, 2012 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced the appointment of Peter F. McAree as Senior Vice President, Chief Financial Officer and Treasurer, effective immediately.  Mr. McAree most recently was Senior Vice President and Chief Financial Officer of Caliper L... 
 Printer Friendly Version
06/27/12Medtronic Wins U.S. Patent Case Against Gore Involving Stent Grafts
MINNEAPOLIS –– June 27, 2012 –– Medtronic, Inc. (NYSE: MDT) announced today that a judge in the Eastern District Court of Virginia last week ruled in Medtronic’s favor in a patent case brought by W.L Gore & Associates, Inc. The patent in question involved a method of making stent grafts, which are implantable medical devices used to treat aortic aneurysms. The judge determined that Medtronic’s stent grafts did not infringe Gore’s U.S. Patent No. 5,810,870. “We’re pleased with the court’s... 
Download PDFPrinter Friendly Version
06/27/12Covidien Launches Campaign to Increase Awareness of Pregnancy-Related Blood Clots
New “1 in 1,000” campaign helps healthcare professionals educate patients about VTE risks during pregnancy, delivery and postpartum WASHINGTON--(BUSINESS WIRE)--Jun. 27, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the launch of its “1 in 1,000” campaign to help educate women about the risk of pregnancy-related blood clots, one of the leading causes of maternal mortality in the developed world.1 The announcement was made at the 2012 annual ... 
 Printer Friendly Version
06/26/12Covidien Completes Acquisition of Oridion Systems Ltd.
DUBLIN--(BUSINESS WIRE)--Jun. 26, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, today said that it has completed the previously announced acquisition of Oridion Systems Ltd. for an aggregate consideration of approximately $310 million, net of cash and investments acquired. Pursuant to the terms of the acquisition agreement, Covidien has acquired all of the outstanding capital stock of O... 
 Printer Friendly Version
06/25/12Covidien plc to Report Third-Quarter Results on July 26, 2012
DUBLIN--(BUSINESS WIRE)--Jun. 25, 2012-- Covidien plc (NYSE: COV) will report third-quarter results on July 26, 2012, before trading begins. The Company will hold a conference call for investors at 8:30 a.m. ET. The call can be accessed in the following ways: At Covidien’s website: http://investor.covidien.com By telephone: For both “listen-only” participants and those participants who wish to take ... 
 Printer Friendly Version
06/21/12Medtronic Stent Graft Chosen by U.S. FDA for Innovative Program
Regulatory Agency Selects Investigational Medical Device for Endovascular Treatment of Thoracic Aortic Aneurysms Involving Branch Vessel for Early Feasibility Pilot Program MINNEAPOLIS –– June 21, 2012 –– The U.S. Food and Drug Administration (FDA) recently selected a stent graft being developed by Medtronic, Inc. (NYSE: MDT) for an early feasibility pilot program that allows for “early clinical evaluation to provide proof of principle and initial clinical safety data.” One of nine devices s... 
Download PDFPrinter Friendly Version
06/21/12Medtronic Increases Its Cash Dividend by 7 Percent
MINNEAPOLIS – June 21, 2012 – The board of directors of Medtronic, Inc. (NYSE: MDT) today approved a 7.2 percent increase in its cash dividend for fiscal year 2013, raising the quarterly amount to $0.26 per share of the company’s common stock for an annual amount of $1.04 per share.   Medtronic’s dividend has more than doubled over the past five years, and today’s announcement marks the company’s 35th consecutive year of increased dividend payments.  Medtronic is a constituent of ... 
Download PDFPrinter Friendly Version
06/21/12Covidien Announces Global Launch of Nellcor™ SpO2 Module for Philips IntelliVue Patient Monitors
Provides Cost-Effective Means to a More Complete Picture of a Patient’s Respiratory Function Status BOULDER, Colo.--(BUSINESS WIRE)--Jun. 21, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, today announced the launch of its Nellcor™ SpO2 single parameter module for use with the Philips IntelliVue patient monitoring platform... 
 Printer Friendly Version
06/20/12Medtronic Statement on Russia PNTR
Russia is one of the fast growing regions for the medical technology industry and for Medtronic. Permanent Normal Trade Relations is a critical step towards ensuring the U.S. benefits from Russia’s WTO accession. Specifically, establishing the PNTR will help ensure Russian’s adherence to the rules of international trade regarding intellectual property rights, as well as science-and risk-based regulations. The more demand for product in Russia, the more support for continued and future investme... 
Download PDFPrinter Friendly Version
06/19/12Covidien Launches World’s First Knotless Suture Reload for Laparoscopic and Single-Incision Procedures
Bariatric practice education program also introduced at ASMBS 2012 SAN DIEGO--(BUSINESS WIRE)--Jun. 19, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the latest additions to its growing bariatric surgery portfolio of products and services designed to improve patient and surgeon experiences with weight loss surgery and other procedures. Covidien's V-Loc™ knotless suturing device is now available as a reload that works with the Company's proprie... 
 Printer Friendly Version
06/18/12Mallinckrodt Announces Co-Promotion Arrangement for DUEXIS®
Collaboration agreement between Mallinckrodt and Horizon Pharma on NSAID/H2 Combination HAZELWOOD, Mo.--(BUSINESS WIRE)--Jun. 18, 2012-- Mallinckrodt, the Pharmaceuticals business of Covidien (NYSE: COV), today announced that it has entered into a co-promotion agreement with Horizon Pharma, Inc. (NASDAQ: HZNP) to promote DUEXIS® (ibuprofen and famotidine). DUEXIS is a proprietary single-tablet combination of the non-steroidal anti-infl... 
 Printer Friendly Version
06/08/12Medtronic Files PMA Application for FDA Approval of MiniMed 530G System Featuring Threshold Suspend Automation
FDA to Review World’s First Insulin Pump with Threshold Suspend – Another Significant Step Toward the Artificial Pancreas FDA to Review World’s First Insulin Pump with Threshold Suspend – Another Significant Step Toward the Artificial Pancreas MINNEAPOLIS – June 8, 2012 –In the next step toward the development of an artificial pancreas, Medtronic, Inc. (NYSE:MDT) today announced that it has filed the final module of its Pre-Market Approval (PMA) application with the U.S. Food and Drug Admin... 
Download PDFPrinter Friendly Version
06/07/12Mallinckrodt and Zogenix Announce Exclusive Co-Promotion Arrangement on SUMAVEL® DosePro®
Collaboration agreement between Mallinckrodt and Zogenix on migraine treatment HAZELWOOD, Mo.--(BUSINESS WIRE)--Jun. 7, 2012-- Mallinckrodt LLC, the Pharmaceuticals business of Covidien (NYSE: COV), today announced that it has entered into a co-promotion agreement with Zogenix Inc. (NASDAQ: ZGNX) for SUMAVEL® DosePro® (sumatriptan injection), a prescription medicine given with a needle-free delivery system to treat adults who ha... 
 Printer Friendly Version
06/06/12Medtronic Launches Endurant® II AAA Stent Graft System in U.S.
Enhanced Medical Device to Repair Abdominal Aortic Aneurysms Expands Physicians’ Options for Treating ‘Silent Killer’ Without Major Surgery MINNEAPOLIS –– June 6, 2012 –– Medtronic, Inc. (NYSE: MDT) announced today the U.S. launch of the Endurant® II AAA Stent Graft System, which recently received approval from the U.S. Food and Drug Administration (FDA) for the minimally invasive treatment of abdominal aortic aneurysms through endovascular repair (EVAR), an alternative to major surgery. The... 
Download PDFPrinter Friendly Version
06/06/12Covidien Funds Educational Grant to Support Brazilian Stroke Network
New Educational and Training Programs Aim to Improve Stroke Care throughout Brazil DUBLIN--(BUSINESS WIRE)--Jun. 6, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that it will support the Brazilian Stroke Network (BSN), a non-governmental organization, through an unrestricted educational grant designed to assist the BSN in its efforts to increase education and awareness about strok... 
 Printer Friendly Version
06/01/12JDRF through the Joint JDRF-Helmsley Charitable Trust Initiative Partners with Medtronic to Advance Continuous Glucose Monitoring Towards Artificial Pancreas Systems
-- Partnership Announced Between Leaders of Artificial Pancreas Research and Development to Develop Novel Redundant Sensor System to Help Improve Glucose Control for People with Diabetes -- NEW YORK, N.Y., June 1, 2012 -- JDRF in collaboration with the Helmsley Charitable Trust (HCT) announced today a partnership with Medtronic, Inc. (NYSE:MDT), a leader in artificial pancreas research and development. The JDRF-HCT Sensor Initiative aims to advance continuous glucose monitoring (CGM) accuracy ... 
Download PDFPrinter Friendly Version
06/01/12Medtronic Announces Date for 2012 Annual Meeting
Shareholders Invited to Attend Annual Meeting on Aug. 23, 2012 MINNEAPOLIS – June 1, 2012 – The board of directors of Medtronic, Inc. (NYSE: MDT), announced that the company’s annual meeting of shareholders will be held at 10:30 a.m., Central Daylight Time, on Thursday, Aug. 23, 2012 at Medtronic World Headquarters, located at 710 Medtronic Parkway, Minneapolis, Minn. Shareholders of record at the close of business on June 25, 2012, will be eligible to vote at the meeting. About Medtronic M... 
Download PDFPrinter Friendly Version
06/01/12CORRECTING and REPLACING Covidien Launches Endo GIA™ Radial Reload with Tri-Staple™ Technology
The Radial Reload allows surgeons to cut and securely staple colon tissue up to 2 cm deeper into the pelvis than the Ethicon Contour®1 Curved Cutter Stapler2 NEW HAVEN, Conn.--(BUSINESS WIRE)--May. 31, 2012-- A multimedia asset accompanying this release has been removed. Endo GIA(TM) Radial Reload with Tri-Staple(TM) Technology (Photo: Business Wire) The release reads: COVIDIEN LAUNCHES ENDO GIA™ RADIAL RELOAD WIT... 
 Printer Friendly Version
05/31/12Medtronic CEO Omar Ishrak to Speak at Goldman Sachs Healthcare Conference
MINNEAPOLIS – May 31, 2012 – Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Goldman Sachs 33rd Annual Global Healthcare Conference on Tuesday, June 5, 2012, in Long Beach, CA. Omar Ishrak, chairman and chief executive officer of Medtronic, will make a presentation about Medtronic beginning at 2:40 p.m. PDT (4:40 p.m. CDT). A live audio webcast of the presentation will be available on June 5, 2012, by clicking on the Inve... 
Download PDFPrinter Friendly Version
05/31/12Covidien to Present at Goldman Sachs Conference
MANSFIELD, Mass.--(BUSINESS WIRE)--May. 31, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, will present at the Goldman Sachs 33rd Global Healthcare Conference in Rancho Palos Verdes, CA, on Thursday, June 7, 2012. José E. Almeida, Chairman, President and Chief Executive Officer, will represent the Company in a session scheduled at 11:00 a.m. ET. A live audio webcast of the presentation can be accessed at... 
 Printer Friendly Version
05/29/12Medtronic SHILLA(TM) Growth Guidance System Receives CE Mark; Launches Across European Economic Area
Novel surgical procedure offers new option for children with life-threatening curvature of spine Amsterdam, The Netherlands –May 29, 2012 – Medtronic, Inc.  (NYSE: MDT) announced today that a novel surgical procedure for children received CE (Conformité Européenne) Mark. The procedure, which can correct and maintain spinal deformities associated with severe, progressive, life-threatening curvature of the spine in young children (early-onset scoliosis) allows natural growth of their bodies... 
Download PDFPrinter Friendly Version
05/25/12Medtronic Resolute® Stent Shows Strong Performance in Heart Disease Patients With and Without Diabetes
Study Results Slated for Presentation in Late-Breaking Clinical Trials Session at Endocrinology Meeting Include Low Event Rates Through Two Years of Follow-Up MINNEAPOLIS –– May 25, 2012 –– According to study results to be featured in Sunday’s late-breaking clinical trials session at the American Association of Clinical Endocrinologists (AACE) 21st Annual Scientific and Clinical Congress in Philadelphia, the Resolute® drug-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT) yields strong perf... 
Download PDFPrinter Friendly Version
05/23/12HeartWare Announces Publication Of Results From U.S. Bridge-To-Transplant Clinical Trial
- Findings support potential of HeartWare® Ventricular Assist System in patients with advanced heart failure - FRAMINGHAM, Mass. and SYDNEY, May 23, 2012 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced the publication of results from ADVANCE, the Company's U.S. clinical trial evaluating the use of the He... 
 Printer Friendly Version
05/23/12Medtronic Foundation Supports New Initiative to Develop National Plans Addressing Noncommunicable Diseases (NCDs)
Grant to Partners In Health creates a program within the Rwandan Ministry of Health to provide planning assistance to six low-income countries  in order to improve access to NCD care MINNEAPOLIS – May 23, 2012 – In a continued commitment to help reduce the global burden of noncommunicable diseases (NCDs) such as cardiovascular disease and diabetes, the Medtronic Foundation is making a $435,000 grant to Partners in Health (PIH) to work with the Rwandan Ministry of Health to establish a t... 
Download PDFPrinter Friendly Version
05/23/12HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart Failure
-Label Expansion Addresses Long-Term Support- FRAMINGHAM, Mass., and SYDNEY, May 23, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies revolutionizing the treatment of advanced heart failure, today announced that it has received an expanded European label for long-term use of the HeartWare® Ventricular Assist System in all patients at risk of death from refractory, end-stage heart ... 
 Printer Friendly Version
05/22/12Covidien Announces Pricing of $1.250 Billion Senior Notes Offering
DUBLIN--(BUSINESS WIRE)--May. 22, 2012-- Covidien plc (NYSE: COV) today announced that its wholly-owned subsidiary, Covidien International Finance S.A. (CIFSA), priced an underwritten offering of $600 million aggregate principal amount of 1.350% senior notes due 2015 and $650 million aggregate principal amount of 3.200% senior notes due 2022. The offering is expected to close on May 30, 2012. The notes will be CIFSA’s senior unsecured ... 
 Printer Friendly Version
05/22/12Medtronic Reports Fourth Quarter Earnings
Revenue of $4.3 Billion Grew 4% on a Constant Currency Basis; 3% as Reported Non-GAAP Diluted EPS Growth of 10%; GAAP Diluted EPS Growth of 31% U.S. Drug-Eluting Stent Revenue of $80 Million Grew 57% on Impressive Resolute™ Integrity® Launch, Doubling U.S. Market Share Emerging Market Revenue Grew 20% on a Constant Currency Basis; 19% as Reported Company Sets Initial FY13 Revenue Growth Outlook and EPS Guidance   MINNEAPOLIS – May 22, 2012 – Medtronic, Inc. (NYSE: MDT) today announ... 
Download PDFPrinter Friendly Version
05/22/12Covidien Announces Senior Notes Offering and Redemption of 5.450% Senior Notes Due October 2012
DUBLIN--(BUSINESS WIRE)--May. 22, 2012-- Covidien plc (NYSE: COV) today announced that its wholly-owned subsidiary, Covidien International Finance S.A. (CIFSA), launched an underwritten offering of senior notes (the “Notes”). These notes will be fully and unconditionally guaranteed on a senior unsecured basis by Covidien plc and its subsidiary, Covidien Ltd. CIFSA intends to use the proceeds from the offering to finance the redemption of all of its ... 
 Printer Friendly Version
05/21/12Covidien Appoints Gregory S. Andrulonis Vice President and Treasurer
DUBLIN--(BUSINESS WIRE)--May. 21, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the appointment of Gregory S. Andrulonis as Vice President and Treasurer, effective immediately. Mr. Andrulonis succeeds Kevin G. DaSilva in this role. Mr. DaSilva will remain Vice President, Group Chief Financial Officer, responsible for finance activities in Covidien’s Respiratory & Monitoring Solutions and... 
 Printer Friendly Version
05/17/12Women Undergoing TAVI Using the Medtronic CoreValve® System Have Similar Survival Benefit as Men
Rigorous Trial Design and Monitoring Provides New Insight to Outcomes for Men and Women with Aortic Stenosis PARIS – MAY 17, 2012 – Medtronic, Inc. (NYSE: MDT) today announced new results from the Medtronic CoreValve ADVANCE Study, which found that women and men benefitted similarly from the Medtronic CoreValve® System. The study, presented at EuroPCR 2012, evaluated patients who were at high-risk for surgical aortic valve replacement. The Medtronic CoreValve System is currently limited to inv... 
Download PDFPrinter Friendly Version
05/17/12Covidien Introduces HALO90 ULTRA Ablation Catheter for Treatment of Barrett’s Esophagus
New, longer radiofrequency ablation catheter treats larger areas of disease SUNNYVALE, Calif.--(BUSINESS WIRE)--May. 17, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the launch of the HALO90 ULTRA Ablation Catheter, the latest addition to the HALO family of catheters for the endoscopic treatment of Barrett’s esophagus. Barrett’s esophagus is a precancerous condition of th... 
 Printer Friendly Version
05/16/12Medtronic IN.PACT Drug-Eluting Balloon Studies Show Significant Benefit of Novel Medical Device in Treating Narrowed Arteries
Randomized Controlled Trial Results Presented At EuroPCR Demonstrate Advantages Over Uncoated Angioplasty Balloons and Drug-Eluting Stents PARIS –– May 16, 2012 –– Adding to the growing body of evidence on a novel interventional cardiovascular device, physicians presented today at EuroPCR 2012 the results of two multicenter, randomized controlled trials, the BELLO and PACIFIER studies, each one showing statistically significant advantages of using an IN.PACT drug-eluting balloon from Medtronic... 
Download PDFPrinter Friendly Version
05/16/12Medtronic Foundation and Project HOPE to Rebuild Town Hospital in Northeastern Japan Devastated by March 2011 Tsunami
Medtronic Foundation Grant Will Enable HOPE to Bring Long-term Stability and Care Millwood, Va. (May 16, 2012) – Medtronic Foundation and Project HOPE today announced a partnership to rebuild the Yamada General Hospital in Japan’s northern coastal town of Yamada one year after it was submerged underwater in the earthquake-triggered tsunami that destroyed the hospital and killed hundreds of people in the town.   The grant from the Medtronic Foundation aims to re-establish the hospita... 
Download PDFPrinter Friendly Version
05/16/12Medtronic receives notification that U.S. Department Of Justice and U.S. Attorney’s office have closed their investigation of activities relating to Infuse® bone graft
Closure Ends Federal Civil and Criminal Investigations of the Company MINNEAPOLIS – MAY 16, 2012 – Medtronic, Inc. (NYSE: MDT) today announced it has been notified by the U.S. Department of Justice (DOJ) and the Office of the United States Attorney for the District of Massachusetts that federal prosecutors have closed their investigation of Medtronic related to INFUSE® Bone Graft. The status of this federal civil and criminal investigation has been regularly reported in Medtronic’s quarterly d... 
Download PDFPrinter Friendly Version
05/15/12Covidien Completes Acquisition of superDimension, Ltd.
DUBLIN--(BUSINESS WIRE)--May. 15, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that it has completed the previously announced acquisition of superDimension, Ltd., for an aggregate consideration of approximately $300 million, with future earn out payments possible. Pursuant to the terms of the acquisition agreement, Covidien has acquired all of the outstanding capital stock of superDimension... 
 Printer Friendly Version
05/15/12Medtronic Announces 2012 Analyst Meeting and Webcast
MINNEAPOLIS – May 15, 2012 – Medtronic (NYSE: MDT) will host an institutional investor and analyst meeting on Friday, June 1, 2012, in New York City from 9:00 a.m. to approximately 1:00 p.m. Eastern Daylight Time.  The meeting will include remarks from the Medtronic management team highlighting the company’s strategy for delivering improved growth and creating long-term shareholder value. Medtronic will host a webcast of the meeting to provide access to all interested shareholders and inv... 
Download PDFPrinter Friendly Version
05/15/12Medtronic Nets New Indications for Resolute Integrity Drug-Eluting Stent in Europe
With Latest Certifications, Company’s Flagship DES Has Broadest Range of Approved Indications in Europe; Study Findings Presented at EuroPCR PARIS –– May 15, 2012 –– As EuroPCR 2012 gets under way today, Medtronic, Inc. (NYSE: MDT) announced that the Resolute Integrity Coronary Stent System has received European regulatory approval for several new indications, making it the drug-eluting stent (DES) with the broadest range of approved indications in Europe. The Resolute Integrity DES is now ex... 
Download PDFPrinter Friendly Version
05/11/12New Data From Landmark Study Shows Cost-Effectiveness of Medtronic Life-Saving CRT-D Therapy in Mildly Symptomatic Heart Failure Patients
Study Reinforces Clinical and Economic Validity of Expanded Indication for Medtronic CRT-D Devices MINNEAPOLIS and BOSTON – May 11, 2012 – Medtronic, Inc. (NYSE: MDT) today announced findings from an economic analysis of the landmark RAFT (Resynchronization / Defibrillation in Ambulatory Heart Failure Trial) trial demonstrating that cardiac resynchronization therapy with defibrillation (CRT-D) is a cost-effective treatment for mildly symptomatic heart failure patients. The findings showed a $3... 
Download PDFPrinter Friendly Version
05/10/12HeartWare International Reports First Quarter 2012 Revenue of $26.3 Million; 47% Increase From $18.0 Million in First Quarter 2011
- Favorable FDA advisory panel recommendation tops list of recent milestones - - Conference call today at 5:00 p.m. U.S. E.T. - FRAMINGHAM, Mass. and SYDNEY, May 10, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $26.3 million for the first quarter ended March 31, 2012.  This represen... 
 Printer Friendly Version
05/10/12Medtronic to Announce Financial Results for Its Fourth Quarter and Fiscal Year 2012
MINNEAPOLIS – May 10, 2012 – Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the fourth quarter and fiscal year 2012 on Tuesday, May 22, 2012. A news release will be issued at approximately 6:15 a.m. Central Time and will be available at www.medtronic.com/newsroom. The earnings news release will include summary financial information for Medtronic’s fourth quarter and fiscal year 2012, which ended April 27, 2012. Medtronic will host a webcast at 7 a.m. Central Ti... 
Download PDFPrinter Friendly Version
05/10/12Study Shows Longer Arrhythmia Detection Window Reduces Shocks for Medtronic Implantable Defibrillator Patients
Late-Breaking Clinical Trial Validates Medtronic Proprietary Device Algorithms MINNEAPOLIS and BOSTON – May 10, 2012 – Medtronic, Inc. (NYSE: MDT) today announced results from the first and only clinical trial to show that Medtronic cardiac devices can safely extend detection time before triggering therapy in primary and secondary prevention patients. The ADVANCE III study, presented today as a late-breaking presentation at Heart Rhythm 2012, the Heart Rhythm Society’s 33rd Annual Scientific S... 
Download PDFPrinter Friendly Version
05/09/12Covidien to Present at Bank of America Merrill Lynch Conference
MANSFIELD, Mass.--(BUSINESS WIRE)--May. 9, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, will present at the Bank of America Merrill Lynch 2012 Health Care Conference in Las Vegas, NV, on Wednesday, May 16, 2012. Bryan Hanson, Group President, Surgical Solutions, will represent the Company in a session scheduled at 8:00 p.m. ET. A live audio webcast of the presentation can be accessed at Covidien’s ... 
 Printer Friendly Version
05/08/12HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
- Company reaches new milestone with over 2,000 HVAD implants worldwide - FRAMINGHAM, Mass. and SYDNEY, May 8, 2012 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that enrollment is complete in ENDURANCE, the Company's pivotal Destination Therapy clinical study to evaluate the use of the HeartWare® Vent... 
 Printer Friendly Version
05/08/12Medtronic Expands Availability of Valiant® Captivia® Stent Graft in Major Global Markets
Implantable Medical Device for Endovascular Repair of Thoracic Aortic Aneurysms Also Being Studied for Minimally Invasive Treatment of Blunt Thoracic Aortic Injuries MINNEAPOLIS –– May 8, 2012 –– Increasing patient access to endovascular repair of aortic aneurysms worldwide, Medtronic, Inc. (NYSE: MDT) is expanding availability of the Valiant® Captivia® Thoracic Stent Graft System in several countries, including China, Japan and the United States. “The expanded offering of the Valiant Captivi... 
Download PDFPrinter Friendly Version
05/08/12Covidien Introduces New Treatment for Drug-Resistant Hypertension
Company to Unveil Novel Renal Denervation System at EuroPCR “Live” Cases with New Irrigated RF Balloon Catheter for Treatment of Hypertension PARIS--(BUSINESS WIRE)--May. 8, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, will unveil its new OneShot™ renal denervation system at the EuroPCR congress in Paris, France, on May 16, 2012. Adding to the Company’s broad and growing vascular therapi... 
 Printer Friendly Version
05/07/12HeartWare Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference to be Webcast
FRAMINGHAM, Mass. and SYDNEY, May 7, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Bank of America Merrill Lynch 2012 Health Care Conference at 3:00 p.m. PDT (6:00 p.m. EDT) on Wednesday, May 16, 2012.  The conference is being held May 15-17, 2... 
 Printer Friendly Version
05/03/12Heartware Schedules First Quarter Conference Call And Webcast
FRAMINGHAM, Mass. and SYDNEY, May 3, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three months ended March 31, 2012, at 5:00 p.m. U.S. Eastern Daylight Time on Thursday, May 10, 2012 (being 7:00 a.m. Australian Eastern Standard Time, on May 11, 2012). The Company plans to release the financial results prior to the conference call. The conference call with management will discuss the Comp... 
 Printer Friendly Version
05/03/12Covidien and GE Healthcare Form Five-Year Collaboration
Bringing Covidien measurement technologies to GE Healthcare patient monitoring helps enhance clinical decision-making BOULDER, Colo. & MILWAUKEE--(BUSINESS WIRE)--May. 3, 2012-- Covidien (NYSE: COV) and GE Healthcare (NYSE: GE), leading global providers of healthcare products and recognized innovators in patient monitoring and respiratory care devices, today announced a five-year, global collaboration to incorporate Covidien mea... 
 Printer Friendly Version
05/01/12Covidien Completes Acquisition of Newport Medical Instruments, Inc.
DUBLIN--(BUSINESS WIRE)--May. 1, 2012-- Covidien plc (NYSE: COV), a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, today announced that it has completed the previously announced acquisition of Newport Medical Instruments, Inc. for an aggregate consideration of approximately $108 million, net of cash and short-term investments acquired. Pursuant to the terms... 
 Printer Friendly Version
04/30/12Eighteen North Suburban High School Graduates Named 2012 Medtronic Scholars
Medtronic Foundation has committed nearly $1.5 million in local scholarships. MINNEAPOLIS – The Medtronic Foundation today announced that 18 students have been selected as 2012 Medtronic Scholars. Each will receive a four-year scholarship totaling $16,000, as well as support services to assist them in their collegiate studies. Comprised of students representing nine Twin Cities’ north suburban high schools, the class of 2012 Medtronic Scholars will be honored at a May 7, 2012 celebration at Me... 
Download PDFPrinter Friendly Version
04/30/12Covidien to Present at Deutsche Bank Conference
MANSFIELD, Mass.--(BUSINESS WIRE)--Apr. 30, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, will present at the Deutsche Bank 37th Annual Health Care Conference in Boston on Monday, May 7, 2012. José E. Almeida, Chairman, President and Chief Executive Officer, will represent the Company in a session scheduled at 2:50 p.m. ET. A live audio webcast of the presentation can be accessed at Covidien’s In... 
 Printer Friendly Version
04/27/12Trial of Medtronic Symplicity™ Renal Denervation System Shows Significant Blood Pressure Reduction, With No Evidence of Renal Impairment, at Six Months Post Treatment
Six Month Pooled Outcomes From Randomized and Crossover Patients Following Renal Denervation Presented at the 22nd Annual Scientific Meeting of the European Society of Hypertension Confirm Previous Symplicity Clinical Trial Findings MINNEAPOLIS and LONDON – April 27, 2012 – Medtronic, Inc., (NYSE: MDT), announced today six month pooled outcomes from randomized and crossover patients in the Symplicity HTN-2 clinical trial following renal denervation with the Symplicity™ renal denervation system... 
Download PDFPrinter Friendly Version
04/27/12Covidien Reports Second-Quarter Results
View PDF Net sales up 5%; Medical Devices sales up 7% Second-quarter diluted GAAP earnings per share from continuing operations were $1.01; excluding specified items, adjusted diluted earnings per share from continuing operations were $1.05, up 13% DUBLIN, Apr 27, 2012 (BUSINESS WIRE) --Covidien plc (NYSE: COV) today reported results for the second quarter of fiscal 2012 (January-March 2012). Second-quarter net sales of $2.95 billion increased 5% from the $2.80 billion reported in the... 
 Printer Friendly Version
04/25/12FDA Advisory Committee Votes in Favor of HeartWare® Ventricular Assist System as Bridge to Transplant for Patients With End-Stage Heart Failure
FRAMINGHAM, Mass. and SYDNEY, April 25, 2012 /PRNewswire via COMTEX/ --HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration's (FDA) Circulatory System Devices Advisory Committee voted 9 to 2 that the benefits outweigh the risks for the use of the HeartWare® Ventricular Assist System as a... 
 Printer Friendly Version
04/25/12HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
FRAMINGHAM, Mass. and SYDNEY, April 25, 2012 /PRNewswire via COMTEX/ --HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN) today announced that NASDAQ has halted trading of the Company's common stock. The U.S. Food and Drug Administration's (FDA) Circulatory System Devices Advisory Committee meets today to review HeartWare's Premarket Approval (PMA) application for the HeartWare® Ventricular Assist System as a bridge to heart transplantation for patients with end-stage heart failure. Hear... 
 Printer Friendly Version
04/24/12Medtronic Named One of America’s Best Corporate Citizens
Medical Technology Leader Ranked in Top 50 on Corporate Responsibility Magazine’s 100 Best Corporate Citizens List MINNEAPOLIS – April 24, 2012 – Medtronic, Inc. is one of America’s best corporate citizens, according to the rankings recently released by Corporate Responsibility magazine. Medtronic made the top 50 list, moving up 16 spots from its 66th ranking in 2011.  “Being a good corporate citizen is an important part of our Mission,” said Omar Ishrak, Medtronic chairman and chief ex... 
Download PDFPrinter Friendly Version
04/17/12Medtronic Announces Global Drug-Eluting Balloon Study
International Research Program Will Collect and Assess Safety and Efficacy Data on IN.PACT Admiral™ Drug-Eluting Balloon in Treatment of Peripheral Artery Disease MINNEAPOLIS and LONDON –– April 17, 2012 –– In conjunction with the Charing Cross International Symposium (CX34), which concludes today in London, Minneapolis-based Medtronic, Inc. (NYSE: MDT) announced its plans for the imminent start of the IN.PACT Global SFA clinical study, an international research program to evaluate the treatme... 
Download PDFPrinter Friendly Version
04/16/12Medtronic Endurant® AAA Stent Graft Shows Durable Performance at Two Years in U.S. Study
Market-Leading Medical Device for Minimally Invasive Treatment of Abdominal Aortic Aneurysms Continues to Demonstrate Strong Safety and Efficacy MINNEAPOLIS and LONDON –– April 16, 2012 –– Bolstering confidence in endovascular repair of abdominal aortic aneurysms (AAA), Medtronic Inc. (NYSE: MDT) announced yesterday the two-year results from its U.S. clinical study of the Endurant AAA Stent Graft System, the global market leader in its product category. Presented at this year’s Charing Cross... 
Download PDFPrinter Friendly Version
04/16/12Medtronic Announces Launch of the POWEREASE™ System
Latest innovation offers power technology for reconstructive spine surgery MEMPHIS, TENN. – April 16, 2012 –Medtronic, Inc. (NYSE: MDT) today announced the initiation of its launch of the POWEREASE™ System, an innovative system of electronic instruments designed specifically for use in instrumented, or reconstructive, spine surgery. This system brings new capability to the operating room through compatibility with two of the leading pedicle screw platforms on the market, the CD HORIZON® SOLERA... 
Download PDFPrinter Friendly Version
04/13/12Medtronic Initiates Landmark U.S. Drug-Eluting Balloon Study
First Patients Treated in Clinical Trial of Novel Medical Device Involving Interventions for Lower-Extremity Peripheral Artery Disease MINNEAPOLIS –– April 13, 2012 –– Expanding its commitment to developing innovative treatments for cardiovascular disease and the evidence to support their adoption, Medtronic, Inc. (NYSE: MDT) announced today the start of the Medtronic IN.PACT SFA II study, the company’s first U.S. clinical trial for its line of IN.PACT drug-eluting balloons. The first patien... 
Download PDFPrinter Friendly Version
04/13/12Medtronic Foundation Launches Online Save-A-Life Simulation To Promote Bystander Response For Cardiac Arrest
Interactive Tool Simulates Sudden Cardiac Arrest Event; Teaches Crucial Steps in Saving a Life MINNEAPOLIS – April 13, 2012 – The Medtronic Foundation's HeartRescue Project has produced an interactive, online experience, the “Save-a-Life Simulator,” to promote proper and timely bystander response to sudden cardiac arrest (SCA).  First person point-of-view videos put the viewer in the shoes of an everyday mall-goer who witnesses a person experiencing SCA. The “choose-your-own-adventure” ... 
Download PDFPrinter Friendly Version
04/10/12Mallinckrodt, a Covidien company, Joins The Partnership at Drugfree.org in Supporting “Wake Up To Medicine Abuse”
ST. LOUIS--(BUSINESS WIRE)--Apr. 10, 2012-- Mallinckrodt, the pharmaceuticals business of Covidien (NYSE: COV), today joined The Partnership at Drugfree.org in supporting the “Wake Up to Medicine Abuse” campaign. The initiative will address youth prescription medicine abuse and how to prevent it. Announced in conjunction with Operation UNITE’s National Rx Drug Abuse Summit this week in Orlando, Florida, “Wake Up To Medicine Abuse” is a nationa... 
 Printer Friendly Version
04/10/12Medtronic Receives FDA Approval to Treat Mildly Symptomatic Heart Failure Patients Through Expanded Indication for CRT-D
Pivotal REVERSE & Landmark RAFT Clinical Trials Demonstrate Reduction in Mortality and Heart Failure Hospitalization Rates in New Patient Population MINNEAPOLIS – April 10, 2012 – Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for its cardiac resynchronization therapy with implantable cardioverter defibrillator (CRT-D) devices. With today’s approval, this advanced therapy can now be used earlier, in a mildly symp... 
Download PDFPrinter Friendly Version
04/05/12Covidien Announces Definitive Agreement to Acquire Oridion Systems Ltd.
DUBLIN--(BUSINESS WIRE)--Apr. 5, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, today announced a definitive agreement to acquire Oridion Systems Ltd. Oridion Systems (SIX Swiss Exchange: ORIDN), based in Jerusalem, Israel, had 2011 sales of $64 million. The Boards of Directors of both companies have unanimously approved the t... 
 Printer Friendly Version
04/04/12Covidien Prevails in Patent Action against Applied Medical Resources
MANSFIELD, Mass.--(BUSINESS WIRE)--Apr. 4, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, announced that it has prevailed against Applied Medical Resources Corp. in a patent action before the U.S. District Court, Central District of California. In granting Covidien’s motion of summary judgment, the District Court ruled that Covidien’s trocar products do not infringe Applied Medical’s patent. In May 20... 
 Printer Friendly Version
04/03/12Covidien Announces Method to Measure Operating Room Ergonomics
Properly designed powered surgical staplers may reduce surgeon fatigue and musculoskeletal issues associated with performing minimally invasive surgeries NEW HAVEN, Conn.--(BUSINESS WIRE)--Apr. 3, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that researchers have developed a new method to measure the physical strain placed on surgeons while performing minimally invasive surgery. ... 
 Printer Friendly Version
03/30/12Medtronic Reaches Settlement Of Shareholder Class Action
MINNEAPOLIS, MN – March 30, 2012 - Medtronic, Inc. (NYSE: MDT) today announced that the company has reached an agreement in principle to settle a previously disclosed federal securities class action. Under the settlement, the company will make a payment of $85 million to resolve all of the class claims. The action, initially filed in December, 2008 against the company and certain current and former officers by the Minneapolis Firefighters Relief Association, had sought damages for alleged misr... 
Download PDFPrinter Friendly Version
03/30/12Osteoarthritis Treatment Guidelines Issued by American College of Rheumatology Discussed Use of Topical NSAIDS for Patients 75 and Older
ST. LOUIS--(BUSINESS WIRE)--Mar. 30, 2012-- The American College of Rheumatology (ACR) Subcommittee on Osteoarthritis Guidelines has approved and issued several updates to clinical practice guidelines for the treatment of osteoarthritis (OA). The new guidelines, published in the April issue of Arthritis Care & Research, conditionally recommend that healthcare providers consider topical nonsteroidal anti-inflammatory drugs (NSAIDs) as one opti... 
 Printer Friendly Version
03/29/12HeartWare International Expands Intellectual Property and Technology Portfolio Through Definitive Agreement to Acquire World Heart Corporation for US$8 Million
FRAMINGHAM, Mass. and SALT LAKE CITY, March 29, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR, ASX: HIN), which develops and manufactures miniaturized ventricular assist devices, and World Heart Corporation (NASDAQ: WHRT), which has been engaged in the development of left ventricular assist devices, announced today that they have entered into a definitive merger agreement under which HeartWare will acquire WorldHeart for consideration of US$8 million, which wi... 
 Printer Friendly Version
03/29/12Covidien Announces Launch of AccuMesh™ Positioning System
Innovative Endomechanical Device Facilitates Insertion, Deployment and Placement of Mesh in Laparoscopic Ventral Hernia Repair NEW YORK--(BUSINESS WIRE)--Mar. 29, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the launch of the AccuMesh™ positioning system. This innovative endomechanical device facilitates insertion, deployment and placement of Parietex™ optimized composite (PCOx) ... 
 Printer Friendly Version
03/26/12Medtronic-Sponsored Study Finds Pacemakers Reduce Fainting in Patients
ACC.12 Late-breaker Shows Promise of Pacemakers through Diminishing Fainting Recurrences in Patients Diagnosed with Syncope MINNEAPOLIS and CHICAGO – March 26, 2012 – Medtronic, Inc. (NYSE: MDT) today announced the results of a double-blind, randomized study, ISSUE-3, which found that patients who suffered from fainting due to neurocardiogenic syncope had fewer fainting occurrences when treated with a Medtronic pacemaker. The results, which found a statistically and clinically significant 57 p... 
Download PDFPrinter Friendly Version
03/26/12Covidien plc to Report Second-Quarter Results on April 27, 2012
DUBLIN--(BUSINESS WIRE)--Mar. 26, 2012-- Covidien plc (NYSE: COV) will report second-quarter results on April 27, 2012, before trading begins. The Company will hold a conference call for investors at 8:30 a.m. ET. The call can be accessed in the following ways: At Covidien’s website: http://investor.covidien.com By telephone: For both “listen-only” participants and those participants who wish to tak... 
 Printer Friendly Version
03/25/12Medtronic Symplicity™ Renal Denervation System Demonstrates Significant and Sustained Blood Pressure Reduction Out to Three Years
Data from Two Clinical Trials Presented at the 61st Annual Scientific Session of the American College of Cardiology Show Consistent Effectiveness and Safety Up to Three Years Abstracts 926-3 and 926-4 MINNEAPOLIS and CHICAGO – March 25, 2012 – Medtronic, Inc. (NYSE: MDT), announced that the Symplicity™ renal denervation system provides safe, significant and sustained blood pressure reduction up to three years in patients with treatment-resistant hypertension, according to data from two clinic... 
Download PDFPrinter Friendly Version
03/24/12Data Presented at ACC Reinforce Positive Clinical Outcomes for Patients Receiving Medtronic’s CoreValve® System
MINNEAPOLIS – MARCH 24, 2012 – Medtronic, Inc. (NYSE: MDT) today announced results from its largest international, prospective, single-arm clinical trial evaluating the Medtronic CoreValve® System in patients with severe aortic stenosis who are at high-risk for surgical aortic valve replacement (SAVR). These data, presented at The American College of Cardiology’s (ACC's) 61st Annual Scientific Session & Expo in Chicago, showed that patients in a real-world setting experienced high procedural... 
Download PDFPrinter Friendly Version
03/24/12Medtronic Resolute® Drug-Eluting Stent Delivers Durable Clinical Outcomes Through Two Years in Major Studies
Recently FDA-Approved, Novel Heart Device Shows Consistently Low Event Rates Across Broad Spectrum of Coronary Artery Disease Patients, Including Those with Diabetes CHICAGO –– March 24, 2012 –– According to new clinical data presented today at ACC.12 –– the 61st Annual Scientific Session & Expo of the American College of Cardiology (ACC) –– the Resolute drug-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT) maintains a powerful and persistent treatment effect for a wide variety of pa... 
Download PDFPrinter Friendly Version
03/22/12Covidien Announces Definitive Agreement to Acquire Newport Medical Instruments, Inc.
DUBLIN--(BUSINESS WIRE)--Mar. 22, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, today announced a definitive agreement to acquire Newport Medical Instruments, Inc. Covidien will acquire all of the outstanding capital stock of Newport Medical, which is privately-owned and based in Costa Mesa, CA, for approximately $108 million... 
 Printer Friendly Version
03/22/12Covidien’s Mallinckrodt Business Launches Morphine Sulfate Oral Solution in U.S.
Pain reliever now available for opioid-tolerant patients ST. LOUIS--(BUSINESS WIRE)--Mar. 22, 2012-- Mallinckrodt, the pharmaceuticals business of Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the launch of its morphine sulfate oral solution for the relief of moderate-to-severe acute and chronic pain in opioid-tolerant patients. The solution is the first generic morphine oral solution to be app... 
 Printer Friendly Version
03/21/12Medtronic CD HORIZON BalanC™ Spinal System Launches Internationally with CE Mark
Unique combination of materials and geometry provide surgeons new options for neutral stabilization spinal cases Barcelona, Spain – March 21, 2012 – Medtronic, Inc. (NYSE:  MDT) announced today the CE (Conformité Européenne) Mark and the international launch of the CD HORIZON BalanC™ Spinal System.  The launch expands the options for physicians outside the United States in treating multi-level spinal surgeries requiring fusion at one or more levels and neutral stabilization (non fu... 
Download PDFPrinter Friendly Version
03/20/12Covidien Announces FDA 510(k) Clearance of Nellcor™ Respiration Rate Software
New Clinical Tool Aids Clinicians in Detecting Early Warning Signs of Respiratory Complications BOULDER, Colo.--(BUSINESS WIRE)--Mar. 20, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to the Company to market the Covidien Nellcor™ ... 
 Printer Friendly Version
03/19/12Covidien Appoints Richard DeRisio Vice President, Global Quality Assurance and Regulatory Affairs
MANSFIELD, Mass.--(BUSINESS WIRE)--Mar. 19, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the appointment of Richard DeRisio as Vice President, Global Quality Assurance and Regulatory Affairs, effective immediately. He will report directly to Michael Sgrignari, Senior Vice President, Quality & Operations. Mr. DeRisio will oversee all of the Company’s activities related to Quality Assuran... 
 Printer Friendly Version
03/19/12Covidien Announces Definitive Agreement to Acquire superDimension, Ltd.
DUBLIN--(BUSINESS WIRE)--Mar. 19, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced a definitive agreement to acquire superDimension, Ltd., a private company based in Herzliya, Israel, that develops minimally invasive interventional pulmonology devices. Covidien will acquire all of the outstanding capital stock of superDimension Ltd., for approximately $300 million, with future earn out p... 
 Printer Friendly Version
03/16/12HeartWare Receives 54-Patient Allotment From FDA Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
FRAMINGHAM, Mass. and SYDNEY, March 16, 2012 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved an IDE (Investigational Device Exemption) Supplement that allows HeartWare to enroll a fourth allotment, of 54 additional patients, ... 
 Printer Friendly Version
03/15/12Medtronic Receives Health Canada License for Deep Brain Stimulation Therapy in Refractory Epilepsy Patients
Another Medtronic First in Neuromodulation in Canada BRAMPTON, ONTARIO and MINNEAPOLIS – March 15, 2012 –Medtronic , Inc. (NYSE: MDT) today announced that it has received from Health Canada a license for Medtronic Deep Brain Stimulation (DBS) Therapy for refractory epilepsy patients. Medtronic DBS therapy for refractory epilepsy delivers controlled electrical pulses to a location inside the brain which is involved in seizures. The Health Canada license was based on data collected in Medtron... 
Download PDFPrinter Friendly Version
03/14/12Medtronic Announces Public Offering of Senior Notes
MINNEAPOLIS– March 14, 2012 – Medtronic, Inc. (NYSE:MDT) today announced a registered offering of $675 million of its 3.125% Senior Notes due 2022 and $400 million of its 4.50% Senior Notes due 2042 (collectively, the "Notes"). Medtronic intends to use the net proceeds for working capital and general corporate purposes, which may include repayment of its indebtedness. The Notes will be unsecured obligations of Medtronic and will rank equally with all of Medtronic's existing and future unsubord... 
Download PDFPrinter Friendly Version
03/14/12Covidien Declares Quarterly Cash Dividend
DUBLIN--(BUSINESS WIRE)--Mar. 14, 2012-- Covidien plc (NYSE: COV) today announced that its Board of Directors has declared a quarterly cash dividend of $0.225 per ordinary share. The dividend is payable on May 7, 2012, to shareholders of record on April 4, 2012. ABOUT COVIDIEN Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value ... 
 Printer Friendly Version
03/13/12Covidien Announces Results from 2012 Annual General Meeting
DUBLIN--(BUSINESS WIRE)--Mar. 13, 2012-- Covidien plc (NYSE: COV) announced the results from today’s Annual General Meeting. Seven proposals were on the meeting agenda: Election of Directors Appointment of Independent Auditors An advisory vote to approve the Company’s executive compensation Authorization of the Company and/or any subsidiary to make market purchase... 
 Printer Friendly Version
03/13/12Medtronic Launches CareLink Pro 3, the First Diabetes Management Software to Offer Advanced Decision Support
Software Offers Therapy Considerations to Help Healthcare Professionals MINNEAPOLIS – March 13, 2012– Medtronic, Inc. today announced the international market launch of CareLink® Pro 3 Therapy Management Software, the first software program to offer advanced decision support to healthcare professionals managing diabetes. The software analyzes data from a patient’s insulin pump, continuous glucose monitoring (CGM) device, and blood glucose meter to identify the most important patient informatio... 
Download PDFPrinter Friendly Version
03/12/12Covidien Announces Study Results Demonstrating Benefits of Minimally Invasive Surgery over Traditional Open Procedures
Separate video presentation shows feasibility of removing a part of a patient’s colon through a single incision NEW HAVEN, Conn.--(BUSINESS WIRE)--Mar. 12, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced results of a retrospective data analysis involving more than 93,000 patients that demonstrate the benefits of laparoscopic surgery over open procedures. A separate video presentation by a colorect... 
 Printer Friendly Version
03/12/12First Patient Enrolled into European Registry for Deep Brain Stimulation in Patients with Refractory Epilepsy
Milestone comes 25 years after the first DBS implant for Tremor MINNEAPOLIS/GENEVA – March 12, 2012 – Medtronic, Inc. (NYSE: MDT) today announced that a patient from Kempenhaeghe-Heeze (The Netherlands) is the first patient to be enrolled into the MORE (MedtrOnic Registry for Epilepsy) Registry which is designed to look at the long-term efficacy, quality of life impact and safety of deep brain stimulation (DBS) in patients with refractory epilepsy. DBS for epilepsy received CE mark for use i... 
Download PDFPrinter Friendly Version
03/09/12Covidien Announces New Surgical Access and Tissue Sealing Devices at SAGES 2012
SAN DIEGO--(BUSINESS WIRE)--Mar. 9, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the launch of three innovative surgical devices designed to provide significant benefits to surgeons and improve patient outcomes. The three are the Versaport™ bladeless optical 5 mm trocar and two new line extensions to the LigaSure™ 5 mm blunt tip sealer/divider portfolio. The Versaport bladeless optical ... 
 Printer Friendly Version
03/08/12Covidien Expands Global Research and Development Presence
Company Opens Four Global R&D Centers to Broaden Innovation Focus and Capabilities MANSFIELD, Mass.--(BUSINESS WIRE)--Mar. 8, 2012-- Covidien (NYSE:COV), a leading global provider of healthcare products, today announced the opening of four research and development (R&D) centers. The R&D facilities are located in: Boulder, Colorado; Hyderabad, India; Irvine, California; and Trevoux, France. "Our investments in these new R... 
 Printer Friendly Version
03/07/12Covidien Peripheral Vascular Stent System Receives FDA Approval
EverFlex™ Self-Expanding Stent Approved for Superficial Femoral and Proximal Popliteal Artery MANSFIELD, Mass.--(BUSINESS WIRE)--Mar. 7, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration (FDA) has approved the EverFlex™ Self-Expanding Peripheral Stent System for use in the superficial femoral artery (SFA) and/or the proximal popliteal artery ... 
 Printer Friendly Version
03/07/12Medtronic CFO Gary Ellis to Speak at Barclays Capital Global Healthcare Conference
MINNEAPOLIS – March 7, 2012 – Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Barclays Capital Global Healthcare Conference on Wednesday, March 14, 2012, in Miami, FL. Gary Ellis, senior vice president and chief financial officer of Medtronic, will make a presentation about Medtronic beginning at 4:45 p.m. ET (3:45 p.m. CT). A live audio webcast of the presentation will be available on March 14, 2012 by clicking on the In... 
Download PDFPrinter Friendly Version
03/06/12Covidien Launches HALO60 Ablation Catheter for Treatment of Barrett's Esophagus
New, smaller radiofrequency ablation catheter eases device access SUNNYVALE, Calif., Mar 06, 2012 (BUSINESS WIRE) --Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the launch of the HALO60 Ablation Catheter, the latest addition to the HALO family of catheters for the endoscopic treatment of Barrett's esophagus. The HALO product line joined the Covidien portfolio earlier when the Company acquired BÂRRX Medi... 
 Printer Friendly Version
03/06/12HeartWare Presentation At The Barclays Capital 2012 Global Healthcare Conference To Be Webcast
FRAMINGHAM, Mass. and SYDNEY, March 6, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Barclays Capital 2012 Global Healthcare Conference at 11:15 am EDT on Tuesday, March 13, 2012.  The conference is being held March 13-14, 2012 at the Loews Miami H... 
 Printer Friendly Version
03/05/12Medtronic Receives CE Mark for Pacemaker Lead That Will Expand Patient Access to MRI Technology
CapSure Sense MRI™ SureScan® Passive Fixation Leads Gives Physicians More MR-Conditional Optionsb MINNEAPOLIS – March 05, 2012 – Medtronic, Inc. (NYSE: MDT) today announced the receipt of CE Mark (Conformité Européenne) and launch of the CapSure Sense MRI™ SureScan® pacing leads, which are approved for use during Magnetic Resonance Imaging (MRI). Medtronic introduced the first MR-Conditional pacemaker system in the world in 2008 and in the U.S. in 2011. The newly approved leads are the smal... 
Download PDFPrinter Friendly Version
03/05/12Covidien Revascularization Device Receives FDA Clearance
Solitaire™ FR device mechanically removes blood clots from blocked vessels after a stroke MANSFIELD, Mass.--(BUSINESS WIRE)--Mar. 5, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that the Solitaire™ FR revascularization device has been cleared by the U.S. Food and Drug Administration. The Solitaire FR device is intended to restore blood flow to the brain in patients suffering acut... 
 Printer Friendly Version
03/01/12Medtronic Seeking Long-Distance Runners Who Benefit From Medical Technology
“Global Heroes” Will Receive Entry and Travel to the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile in October MINNEAPOLIS – March 01, 2012– Medtronic, Inc. (NYSE: MDT) announced today it is recruiting runners from around the world who benefit from medical technology to participate in the seventh annual Medtronic Global Heroes program. Up to 25 runners will be selected to receive a paid entry for themselves and a guest to the Medtronic Twin Cities Marathon or the Medtronic TC 10 Mile a... 
Download PDFPrinter Friendly Version
02/29/12Study of Next Step Toward Artificial Pancreas From Medtronic Meets Efficacy Endpoints
World’s First Insulin Pump with Low Glucose Suspend Showed Reduces Time Spent in Low Threshold Range MINNEAPOLIS – February 29, 2012 –In the next step toward the development of an artificial pancreas, Medtronic, Inc. (NYSE:MDT) today announced that the results of the in-clinic ASPIRE (Automation to Simulate Pancreatic Insulin REsponse) study have been published online and in the March edition of Diabetes Technology & Therapeutics. The ASPIRE study met its efficacy endpoints and showed a 19% re... 
Download PDFPrinter Friendly Version
02/28/12Covidien to Present at Raymond James Conference
MANSFIELD, Mass.--(BUSINESS WIRE)--Feb. 28, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, will present at the Raymond James 33rd Annual Institutional Investors Conference in Orlando, Florida, on March 6, 2012. Charles J. Dockendorff, Executive Vice President and Chief Financial Officer, will represent the Company in a presentation scheduled to begin at 8:40AM ET. A live audio webcast of the presentation... 
 Printer Friendly Version
02/23/12Medtronic CFO Gary Ellis to Speak at Citi Healthcare Conference
MINNEAPOLIS – February 23, 2012 – Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Citi Healthcare Conference on Monday, February 27, 2012, in New York, NY. Gary Ellis, senior vice president and chief financial officer of Medtronic, will make a presentation about Medtronic beginning at 4:00 p.m. ET (3:00 p.m. CT). A live audio webcast of the presentation will be available on February 27, 2012 by clicking on the Investors l... 
Download PDFPrinter Friendly Version
02/21/12Medtronic Reports Third Quarter Earnings
Revenue of $3.9 Billion Driven by International Revenue Growth of 6% on a Constant Currency Basis, 7% as Reported Non-GAAP Diluted EPS of $0.84, GAAP Diluted EPS of $0.88 Free Cash Flow Exceeds $1.0 Billion, GAAP Cash Flow from Operations of $1.2 Billion Reiterates Revenue Outlook and Tightens Diluted EPS Guidance MINNEAPOLIS – Feb. 21, 2012 – Medtronic, Inc. (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2012, which ended January 27, 2012. The company re... 
Download PDFPrinter Friendly Version
02/21/12Covidien to Present at Upcoming Investor Conferences
MANSFIELD, Mass.--(BUSINESS WIRE)--Feb. 21, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that Charles J. Dockendorff, Executive Vice President and Chief Financial Officer, will represent the Company at two upcoming conferences: Citi 2012 Global Health Care Conference February 28, 2012 – New York, NY 2:30PM ET RBC Capital Markets Healthcare Conference February 29, 2012 – New ... 
 Printer Friendly Version
02/20/12Medtronic Resolute Integrity™ Drug-Eluting Stent Obtains FDA Approval for Treating Coronary Artery Disease
Distinguished by Superior Deliverability and Diabetes Indication, New Heart Device Becomes Available to Cath Labs Nationwide MINNEAPOLIS –– February 20, 2012 –– Advancing the clinical practice of interventional cardiovascular medicine, Medtronic Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of the Resolute Integrity™ Drug-Eluting Stent (DES) for the treatment of coronary artery disease (CAD). The new heart device’s FDA approval stems from the results of ... 
Download PDFPrinter Friendly Version
02/16/12Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2012
MINNEAPOLIS – February 16, 2012 – The board of directors of Medtronic, Inc. (NYSE:MDT) today approved a cash dividend of $0.2425 per share of the Company’s common stock. The dividend is payable on April 27, 2012, to shareholders of record at the close of business on April 6, 2012. About Medtronic Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around th... 
Download PDFPrinter Friendly Version
02/16/12HeartWare International Reports Fourth Quarter 2011 Revenues of $23.1 Million; Full Year 2011 Revenues of $82.8 Million; 50% Increase From $55.2 Million in 2010
- Conference call today at 8:00 a.m. U.S. ET - FRAMINGHAM, Mass. and SYDNEY, Feb. 16, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, announced revenue of $23.1 million for the fourth quarter ended December 31, 2011, as compared to $20.9 million for the fourth quarter of 2010.  For the fiscal year 2011, the Company... 
 Printer Friendly Version
02/14/12HeartWare Announces Date for FDA Advisory Committee Panel
- HeartWare Ventricular Assist Device to be Reviewed on April 25, 2012 by FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee - FRAMINGHAM, Mass. and SYDNEY, Feb. 14, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, announced today that a U.S. Food and Drug Administration (... 
 Printer Friendly Version
02/13/12Medtronic Launches Two New Clinical Programs to Evaluate the Use of Symplicity™1 Renal Denervation System Across Multiple Conditions
MINNEAPOLIS – February 13, 2012 – Medtronic, Inc. (NYSE: MDT) announced today the start of two clinical initiatives evaluating the broader, real-world clinical use of the company’s Symplicity™ renal denervation system across multiple conditions. Furthering its leadership in the development of renal denervation therapy, Medtronic launched the Global SYMPLICITY Patient Registry, which will evaluate the real-world, long-term impact of renal denervation in more than 5,000 patients, as well as SYMPLI... 
Download PDFPrinter Friendly Version
02/10/12Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2012
MINNEAPOLIS – February 10, 2012 – Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the third quarter of its fiscal year 2012 on Tuesday, February 21, 2012. A news release will be issued at approximately 6:15 a.m. Central Time and will be available at www.medtronic.com/newsroom. The earnings news release will include summary financial information for Medtronic’s third quarter ended January 27, 2012. Medtronic will host a webcast at 7 a.m. Central Time to discuss f... 
Download PDFPrinter Friendly Version
02/09/12Covidien to Present at Leerink Swann Conference
MANSFIELD, Mass.--(BUSINESS WIRE)--Feb. 9, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, will present at the Leerink Swann 2012 Global Healthcare Conference in New York, New York, on February 16, 2012. Charles J. Dockendorff, Executive Vice President and Chief Financial Officer, will discuss the Company in a presentation scheduled to begin at 8:30AM ET. A live audio webcast of the presentation can be ac... 
 Printer Friendly Version
02/08/12Medtronic Stent Resulted in 90% Freedom from Reinterventions in Narrowed Leg Arteries at 12 Months in International Study
New Clinical Data Presented for First Time at Medical Meetings in U.S. and Europe Show Durable Vessel Patency in Treating Atherosclerotic Lesions of Superficial Femoral Artery MINNEAPOLIS –– February 8, 2012 –– Consistent with its commitment to developing better treatments for peripheral arterial disease (PAD),Medtronic Inc. (NYSE: MDT) today announced the one-year results of an international study of the Complete SE (self-expanding) vascular stent for the treatment of atherosclerosis in the... 
Download PDFPrinter Friendly Version
02/06/12HeartWare Schedules Fourth Quarter Conference Call and Webcast
FRAMINGHAM, Mass. and SYDNEY, Feb. 6, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three and 12 months ended December 31, 2011, at 8:00 a.m. U.S. Eastern Standard Time on Thursday, February 16, 2012 (being midnight Australian Eastern Daylight Time, between February 16 and February 17, 2012). The Company plans to release the financial results prior to the conference call. T... 
 Printer Friendly Version
02/01/12Results from Solitaire with the Intention for Thrombectomy (SWIFT) Study Announced at the International Stroke Conference on February 3
Covidien:WHO:Jeffrey Saver, MD SWIFT, Lead Author Professor of Neurology and Director UCLA Stroke Center, David Geffen School of Medicine University of California, Los Angeles WHAT:Results from the Solitaire with the Intention for Thrombectomy (SWIFT) Study will be announced at a press conference at 8AM CT – followed by a late breaking trial presentation at 12 PM CT. The Solitaire™ FR Revascularization Device is a stent-based mechanical thrombectomy system from Covidien. It combines the abi... 
 Printer Friendly Version
02/01/12Medtronic Announces First Patient Enrollment in Clinical Trial Assessing Guideline-Based Heart Failure Management in Primary Care Setting
IMPROVE HF Bridge Study Will Examine Specific Gaps in Implementation of Guideline-Recommended Treatment in Heart Failure Patients Post-Hospital Discharge MINNEAPOLIS – February 1, 2012 – Medtronic, Inc. (NYSE: MDT) today announced the initiation and first patient enrollment in a clinical study that will evaluate gaps in the implementation of evidence-based treatment guidelines among chronic heart failure patients post-hospital discharge. The IMPROVE HF Bridge Study will analyze approximately... 
Download PDFPrinter Friendly Version
01/30/12Medtronic Announces FDA Approval of DF4 High-Voltage Connector System for Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Devices
New System Builds On Sprint Quattro® Lead, Adding to the Company’s Portfolio of Innovative Technologies Proven to Treat Heart Rhythm Disorders MINNEAPOLIS – January 30, 2012 – Medtronic, Inc. (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval and launch of the DF4 High-Voltage Connector System, a right ventricular lead and connector used with implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) to detect and... 
Download PDFPrinter Friendly Version
01/30/12Data Presented at STS Reinforce Positive Clinical Outcomes for Medtronic CoreValve® System Using Direct Aortic Approach
Multicenter Experience Demonstrates Surgical Approach, with Recent CE Mark, is a Feasible Alternative for Transcatheter Aortic Valve Implantation MINNEAPOLIS – January 30, 2012 – Medtronic, Inc. (NYSE: MDT) today issued a statement on the results of two studies evaluating the use of the Medtronic CoreValve® System delivered through the direct aortic implantation approach. Data presented at the Society of Thoracic Surgeons (STS) 48th Annual Meeting demonstrate positive outcomes when the CoreV... 
Download PDFPrinter Friendly Version
01/30/12Covidien Revascularization Device Approved for Interventional Management of Stroke Trial
Physicians request Solitaire™ FR device for randomized, open-label multi-center study MANSFIELD, Mass.--(BUSINESS WIRE)--Jan. 30, 2012-- Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that the Solitaire™ FR Revascularization Device has been approved for investigational use in the Interventional Management of Stroke (IMS III) trial. The Solitaire FR device was approved by the IMS III Executive Com... 
 Printer Friendly Version
01/27/12Medtronic Launches New Minimally Invasive Cardiac Surgery Products Through Exclusive Distribution Agreement with Miami Instruments
MINNEAPOLIS – January 27, 2012 – Medtronic, Inc. (NYSE: MDT) today announced that it has entered into an exclusive distribution agreement with Miami Instruments, LLC – a company focused on the design of innovative surgical instruments for minimally invasive cardiac surgery (MICS) procedures – and has introduced the company’s first two products in the U.S. The first products launched are the Joseph Lamelas Knot Pusher™, which is designed to simplify the delivery and tying of secure suture knots... 
Download PDFPrinter Friendly Version
01/26/12Covidien Reports First-Quarter Results
View PDF Net sales up 5%; Medical Devices sales up 6% First-quarter diluted GAAP earnings per share from continuing operations were $1.02; excluding specified items, adjusted diluted earnings per share from continuing operations were $1.13, up 19% Fiscal 2012 sales guidance updated DUBLIN--(BUSINESS WIRE)--Jan. 26, 2012-- Covidien plc (NYSE: COV) today reported results for the first quarter of fiscal 2012 (October-December 2011). First-quarter net sales of $2.90 billion increased ... 
 Printer Friendly Version
01/24/12Clinical Data for DURABILITY II Study Presented at ISET 2012
MIAMI--(BUSINESS WIRE)--Jan. 24, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that one-year results on the use of its EverFlex™ stent for superficial femoral artery stenting were presented here during the International Symposium on Endovascular Therapy (ISET) Conference. Presenting the data was co-National Principal Investigator Jon Matsumura, MD, of the Division of Vascular Surgery, Universit... 
 Printer Friendly Version
01/24/12Medtronic Completes Enrollment of Extreme Risk Patient Group in CoreValve® U.S. Pivotal Trial
CoreValve U.S. Trial to Continue Enrolling Patients in High Risk Study, and Will Maintain Therapy Access to Extreme Risk Patients via Continued Access Phase of Trial MINNEAPOLIS – January 24, 2012 – Medtronic, Inc. (NYSE: MDT) today announced it has completed patient enrollment in the extreme risk study in its CoreValve U.S. Pivotal Trial. The company also received approval from the U.S. Food and Drug Administration (FDA) for an extended investigation (under the FDA’s Continued Access Policy... 
Download PDFPrinter Friendly Version
01/24/12First Patient Enrolled in Medtronic-Supported Head-To-Head Clinical Trial Comparing Cryoballoon Ablation to RF Ablation for Paroxysmal Atrial Fibrillation
MINNEAPOLIS – January 24, 2012 – Medtronic, Inc. (NYSE: MDT) today announced the first patient was enrolled in the FIRE AND ICE clinical trial, which is a prospective, randomized, multinational head-to-head clinical trial comparing the long-term safety, effectiveness and ease of use of the Medtronic Arctic Front®Cardiac CryoAblation System compared to the Biosense Webster CARTO® System Guided THERMOCOOL® Catheter to treat patients with symptomatic paroxysmal atrial fibrillation. Results from the... 
Download PDFPrinter Friendly Version
01/23/12Covidien Releases Clinical Data on Plaque Excision for the Treatment of Calcified Lesions
Final Results from DEFINITIVE Ca++ Clinical Study Presented at ISET 2012 MIAMI--(BUSINESS WIRE)--Jan. 23, 2012-- Covidien (NYSE:COV), a leading global provider of healthcare products, today released the results of the DEFINITIVE Ca++ study. DEFINITIVE Ca++ assessed the safety and effectiveness of the SilverHawk™ LS-C/TurboHawk™ Peripheral Plaque Excision Systems when used in conjunction with the SpiderFX™ Embolic Protection System to t... 
 Printer Friendly Version
01/23/12Medtronic Announces 510(k) Clearance for the Aquamantys SBS 5.0 Sheathed Bipolar Sealer for Spine Surgery
MINNEAPOLIS – January 23, 2012 – Medtronic, Inc. (NYSE: MDT) announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for the Aquamantys® SBS 5.0 Sheathed Bipolar Sealer, a new addition to the spine portfolio of the company’s Advanced Energy business. The SBS 5.0 Sheathed Bipolar Sealer gives spine surgeons the ability to optimize speed and continuity in surgical cases by providing hemostatic sealing capabilities for both incised soft tissue (e.g., cut ... 
Download PDFPrinter Friendly Version
01/23/12Covidien Appoints New Leader for Vascular Therapies Business
MANSFIELD, Mass.--(BUSINESS WIRE)--Jan. 23, 2012-- Covidien (NYSE: COV), a leading global supplier of healthcare products, today announced that Stacy Enxing Seng has been appointed President of the Company’s Vascular Therapies Global Business Unit. She will report directly to Peter L. Wehrly, Senior Vice President and Group President, Respiratory & Monitoring Solutions and Vascular Therapies. Enxing Seng, 47, will be responsible for managing ... 
 Printer Friendly Version
01/20/12Covidien CEO Elected Chairman of the Board
CEO and President José E. Almeida Assumes Additional Duties DUBLIN--(BUSINESS WIRE)--Jan. 20, 2012-- Covidien plc (NYSE: COV) today announced that its Board of Directors has elected President and Chief Executive Officer José E. Almeida to the additional position of Chairman of the Board, effective March 13, 2012. Jose E. Almeida, Covidien plc (Photo: Business Wire) Mr. Almeida will succeed Richard J. Meelia, who has serve... 
 Printer Friendly Version
01/19/12Covidien Declares Quarterly Cash Dividend
DUBLIN--(BUSINESS WIRE)--Jan. 19, 2012-- Covidien plc (NYSE: COV) today announced that its Board of Directors has declared a quarterly cash dividend of $0.225 per ordinary share. The dividend is payable on February 22, 2012, to shareholders of record on January 30, 2012. ABOUT COVIDIEN Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers ... 
 Printer Friendly Version
01/19/12Covidien Provides Update on Voluntary Recall of BIS™ Bilateral Sensors
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 19, 2012-- On November 8, 2011, Covidien initiated a voluntary recall of certain lots of its BIS™ Bilateral Sensors, due to a modification which inadvertently reversed the reference and left eye electrode. This modification could potentially cause a change in the performance of BIS monitoring systems when these sensors are used, resulting in the inaccurate calculation and presentation of processed EEG information... 
 Printer Friendly Version
01/17/12 Medtronic Endurant® II AAA Stent Graft System Launches Internationally With CE Mark
Enhanced Medical Device to Repair Abdominal Aortic Aneurysms Without Open Surgery Expands Physicians’ Options for Treating ‘Silent Killer’ MINNEAPOLIS –– Jan. 17, 2012 –– Medtronic Inc. (NYSE: MDT) today announced the CE (Conformité Européenne) mark and international launch of the Endurant® II AAA Stent Graft System, which meaningfully expands the options physicians outside the United States have to treat patients with abdominal aortic aneurysms through a minimally invasive technique called e... 
Download PDFPrinter Friendly Version
01/16/12Covidien Contraindicates the Use of Duet TRSTM for Thoracic Surgery, Implements a Voluntary Recall
MANSFIELD, Mass.--(BUSINESS WIRE)--Jan. 16, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that it is conducting a voluntary recall of all production lots for the Duet TRSTM Universal Straight and Articulating Single Use Loading Units, with respect to the use of this product family in the thoracic cavity. “After receiving reports connecting the use of the Duet TRS with patient deaths afte... 
 Printer Friendly Version
01/12/12Covidien Appoints Mark Trudeau President of Pharmaceuticals Segment
DUBLIN--(BUSINESS WIRE)--Jan. 12, 2012-- Covidien plc (NYSE:COV), a leading global provider of healthcare products, today announced the appointment of Mark Trudeau as president of its Pharmaceuticals segment and a senior vice president of the Company, effective February 1. Covidien is one of the world’s largest producers of bulk acetaminophen, the largest U.S. supplier of opioid pain medications and among the top 10 generic drug manufactur... 
 Printer Friendly Version
01/11/12Covidien Donates Additional $1 Million to Support Haitian Hospital
Company’s Contributions to Partners In Health for Haiti Now Total $3.5 Million MANSFIELD, Mass.--(BUSINESS WIRE)--Jan. 11, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced an additional $1 million in-kind contribution to non-profit Partners In Health (PIH) to provide medical supplies for a new, state-of-the-art hospital in Mirebalais, Haiti, that is scheduled to open this year. ... 
 Printer Friendly Version
01/09/12HeartWare and Dualis MedTech Announce Agreement to Develop Fully Implantable Ventricular Assist System
FRAMINGHAM, Mass. and SYDNEY, Jan. 9, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, and Dualis MedTech GmbH, a subsidiary of AVRA Surgical, Inc., today announced an agreement to develop ventricular assist devices with wireless, transcutaneous energy transfer system (TETS) technology exclusively for HeartWare. ... 
 Printer Friendly Version
01/05/12Covidien Completes Acquisition of BÂRRX Medical, Inc.
DUBLIN--(BUSINESS WIRE)--Jan. 5, 2012-- Covidien plc (NYSE: COV), a leading global provider of healthcare products, today announced that it has completed the previously announced acquisition of BÂRRX Medical, Inc., for an aggregate consideration of approximately $325 million, net of cash and short-term investments acquired. Pursuant to the terms of the acquisition agreement, Covidien will acquire all of the outstanding capital stock of BÂR... 
 Printer Friendly Version
01/04/12HeartWare to Webcast Presentation at the 30th Annual J.P. Morgan Healthcare Conference
FRAMINGHAM, Mass. and SYDNEY, Jan. 4, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 30th Annual J.P. Morgan Healthcare Conference at 11:00 a.m. PST on Monday, January 9, 2012.  The conference is being held January 9-12, 2012 at the Westin St. F... 
 Printer Friendly Version
01/04/12Medtronic Launches First-Of-Its-Kind mySentry™ Remote Glucose Monitor
mySentry Allows Caregivers to See Real-Time Insulin Pump Information and Glucose Trends from Another Room   MINNEAPOLIS – January 4, 2012 – Today, Medtronic, Inc. (NYSE:MDT) announced U.S. Food and Drug Administration (FDA) approval and U.S. market launch of the first-of-its-kind mySentry™ Remote Glucose Monitor, which allows a parent or caregiver to monitor from another room a patient’s MiniMed Paradigm® REAL-Time Revel™ System. The remote glucose monitor also marks the launch of a n... 
Download PDFPrinter Friendly Version
01/04/12Covidien plc to Report First-Quarter Results on January 26, 2012
DUBLIN--(BUSINESS WIRE)--Jan. 4, 2012-- Covidien plc (NYSE: COV) will report first-quarter results on January 26, 2012, before trading begins. The Company will hold a conference call for investors at 8:30 a.m. ET. The call can be accessed in the following ways: At Covidien’s website: http://investor.covidien.com By telephone: For both “listen-only” participants and those participants who wish to take part ... 
 Printer Friendly Version
01/03/12Covidien to Present at J.P. Morgan Healthcare Conference
MANSFIELD, Mass.--(BUSINESS WIRE)--Jan. 3, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, will present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on January 9, 2012. José E. Almeida, President and Chief Executive Officer, will discuss the Company in a presentation scheduled to begin at 11:30AM ET. A live audio webcast of the presentation can be accessed at Covidien’s ... 
 Printer Friendly Version
X